157 results on '"Tomazic PV"'
Search Results
2. Positioning the principles of precision medicine in care pathways for allergic rhinitis and chronic rhinosinusitis – A EUFOREA‐ARIA‐EPOS‐AIRWAYS ICP statement
- Author
-
Hellings, P. W., Fokkens, W. J., Bachert, C., Akdis, C. A., Bieber, T., Agache, I., Bernal‐Sprekelsen, M., Canonica, G. W., Gevaert, P., Joos, G., Lund, V., Muraro, A., Onerci, M., Zuberbier, T., Pugin, B., Seys, S. F., Bousquet, J., Aberer, W, Agache, I, Akdis, CA, Akdis, M, Alobid, I, Ankri, J, Annesi‐Maesano, I, Ansotegui, IJ, Anto, JM, Arnavielhe, S, Arshad, H, Asarnoj, A, Avolio, F, Bachert, C, Bachert, C, Baiardini, I, Barbagallo, M, Barbara, C, Baroody, F, Bateman, ED, Bedbrook, A, Beghé, B, Bel, EH, Bennoor, KS, Benson, M, Bergmann, KC, Bewick, M, Bialoszewski, AZ, Bieber, T, Bindslev‐Jensen, C, Bjermer, L, Blain, H, Blasi, F, Boner, AL, Bonini, M, Bonini, S, Bosnic‐Anticevich, S, Bosse, I, Bouchard, J, Boulet, LP, Bourret, R, Bousquet, J, Bousquet, PJ, Braido, F, Briggs, AH, Brightling, CE, Brozek, J, Bucca, C, Buhl, R, Bunu, C, Burte, E, Bush, A, Caballero‐Fonseca, F, Caimmi, DP, Calderon, MA, Camargos, PA, Camuzat, T, Canonica, GW, Cardona, V, Carlsen, KH, Carr, W, Carreiro‐Martins, P, Carriazo, AM, Casale, T, Cepeda Sarabia, AM, Cervin, A, Cesari, M, Chatzi, L, Chavannes, NH, Chiron, R, Chivato, T, Chkhartishvili, E, Chuchalin, AG, Chung, KF, Ciprandi, G, Cohen, N, Conzález Diaz, S, Cox, L, Crooks, G, Cruz, AA, Custovic, A, Dahl, R, Dahlen, SE, Darsow, U, De Carlo, G, De Manuel Keenoy, E, de Sousa, JC, De Vries, G, Dedeu, T, Deleanu, D, Demoly, P, Denburg, JA, Devillier, P, Didier, A, Dinh‐Xuan, AT, Dokic, D, Douagui, H, Douglas, R, Dray, G, Du Toit, G, Dubakiene, R, Durham, SR, Dykewicz, MS, Eklund, P, El‐Gamal, Y, Ellers, E, Emuzyte, R, Farrell, J, Fink Wagner, A, Fiocchi, A, Fletcher, M, Fokkens, WJ, Fonseca, J, Forastiere, F, Gaga, M, Gamkrelidze, A, Gemicioğlu, B, Georgalas, C, Gereda, JE, Gevaert, P, Goossens, H, Grisle, I, Guldemond, NA, Gutter, Z, Guzmán, MA, Haahtela, T, Harvey, R, Heinrich, J, Hellings, PW, Hellings, PW, Hellquist‐Dahl, B, Hopkins, C, Horak, F, Hourihane, JO, Humbert, M, Hyland, M, Iaccarino, G, Illario, M, Jares, EJ, Jeandel, C, Johnston, SL, Jonquet, O, Joos, G, Joos, G, Jung, KS, Just, J, Jutel, M, Kaidashev, I, Kalayci, O, Kalogjera, L, Kalyoncu, AF, Kardas, P, Keil, T, Keith, PK, Kerkhof, M, Kern, B, Kerstjens, HA, Khaitov, M, Khaltaev, N, Klimek, L, Kogevinas, M, Kolek, V, Koppelman, GH, Kowalski, M, Kowalski, ML, Kuitunen, M, Kull, I, Kuna, P, Kvedariene, V, Lambrecht, B, Larenas‐Linnemann, D, Lau, S, Laune, D, Le, LT, Li, J, Lieberman, P, Lipworth, B, Lodrup Carlsen, KC, Louis, R, Lund, VJ, Lupinek, C, MacNee, W, Magar, Y, Magnan, A, Mahboub, B, Maier, D, Majer, I, Malva, J, Manning, P, Marshall, GD, Masjedi, MR, Mathieu‐Dupas, E, Maurer, M, Mavale‐Manuel, S, Melén, E, Melo‐Gomes, E, Meltzer, EO, Mercier, J, Merk, H, Miculinic, N, Mihaltan, F, Milenkovic, B, Millot‐Keurinck, J, Mohammad, Y, Momas, I, Morais‐Almeida, M, Mösges, R, Mullol, J, Mullol, J, Muraro, A, Murray, R, Naclerio, R, Nadif, R, Namazova‐Baranova, L, Neffen, H, Nekam, K, Nieto, A, Niggemann, B, Nogueira‐Silva, L, Nogues, M, Nyembue, TD, OʼHehir, RE, Ohta, K, Okamoto, Y, Okubo, K, Olive‐Elias, M, Ouedraogo, S, Paggiaro, P, Pali‐Schöll, I, Palkonen, S, Panzner, P, Papadopoulos, NG, Papi, A, Park, HS, Passalacqua, G, Pawankar, R, Pedersen, S, Pereira, AM, Pfaar, O, Picard, R, Pigearias, B, Pin, I, Plavec, D, Pohl, W, Popov, TA, Portejoie, F, Postma, D, Potter, P, Poulsen, LK, Price, D, Price, D, Rabe, KF, Raciborski, F, Riechelmann, H, Robalo‐Cordeiro, C, Roberts, G, Rodenas, F, Rodriguez‐Mañas, L, Rolland, C, Roman Rodriguez, M, Romano, A, Rosado‐Pinto, J, Rosario, N, Rottem, M, Ryan, D, Samolinski, B, Sanchez‐Borges, M, Sastre‐Dominguez, J, Scadding, GK, Schlosser, R, Schmid‐Grendelmeier, P, Schunemann, HJ, Scichilone, N, Senior, B, Serrano, E, Sheikh, A, Shields, M, Simons, FER, Siroux, V, Sisul, JC, Skrindo, I, Smit, HA, Solé, D, Sooronbaev, T, Spranger, O, Stellato, C, Stelmach, R, Sterk, PJ, Strandberg, T, Sunyer, J, Thijs, C, Thomas, M, Todo‐Bom, A, Tomazic, PV, Toskala, E, Triggiani, M, Valenta, R, Valero, A, Valiulis, A, Valovirta, E, van Eerd, M, van Ganse, E, van Hage, M, van Wick, RG, Vandenplas, O, Varona, LL, Vazankari, T, Vellas, B, Ventura, MT, Vezzani, G, Viegi, G, Voegels, R, Vontetsianos, T, Wagenmann, M, Wahn, U, Walker, S, Wang, DY, Wang, Y, Werfel, T, Whalley, B, Wickman, M, Williams, DM, Williams, S, Wilson, N, Wormald, PJ, Wright, J, Yawn, BP, Yiallouros, PK, Yorgancioglu, A, Young, I, Yusuf, OM, Zaidi, A, Zar, HJ, Zernotti, ME, Zhang, L, Zhong, N, Zidarn, M, and Zuberbier, T
- Published
- 2017
- Full Text
- View/download PDF
3. Adherence to treatment in allergic rhinitis using mobile technology. the mask study
- Author
-
Menditto, E, Costa, E, Midao, L, Bosnic-Anticevich, S, Novellino, E, Bialek, S, Briedis, V, Mair, A, Rajabian-Soderlund, R, Arnavielhe, S, Bedbrook, A, Czarlewski, W, Annesi-Maesano, I, Anto, JM, Devillier, P, De Vries, G, Keil, T, Sheikh, A, Orlando, V, Larenas-Linnemann, D, Cecchi, L, De Feo, G, Stellato, C, Fonseca, J, Malva, J, Morais-Almeida, M, Pereira, AM, Todo-Bom, AM, Kvedariene, V, Valiulis, A, Bergmann, KC, Klimek, L, Mosges, R, Pfaar, O, Zuberbier, T, Cardona, V, Mullol, J, Papadopoulos, NG, Prokopakis, EP, Bewick, M, Ryan, D, Roller-Wirnsberger, RE, Tomazic, PV, Cruz, AA, Kuna, P, Samolinski, B, Fokkens, WJ, Reitsma, S, Bosse, I, Fontaine, JF, Laune, D, Haahtela, T, Toppila-Salmi, S, Bachert, C, Hellings, PW, Melen, E, Wickman, M, Bindslev-Jensen, C, Eller, E, O'Hehir, RE, Cingi, C, Gemicioglu, B, Kalayci, O, Ivancevich, JC, Bousquet, J, Aberer, W, Agache, I, Akdis, CA, Akdis, M, Aliberti, MR, Almeida, R, Amat, F, Angles, R, Ansotegui, IJ, Arnavielle, S, Asayag, E, Asarnoj, A, Arshad, H, Avolio, F, Bacci, E, Baiar-Dini, I, Barbara, C, Barbagallo, M, Baroni, I, Barreto, BA, Basagana, X, Bateman, ED, Bedolla-Barajas, M, Beghe, B, Bel, EH, Bennoor, KS, Benson, M, Bertorello, L, Bialoszewski, AZ, Bieber, T, Bjermer, L, Blain, H, Blasi, F, Blua, A, Marciniak, MB, Bogus-Buczynska, I, Boner, AL, Bonini, M, Bonini, S, Bosnic-Anticevich, CS, Bouchard, J, Boulet, LP, Bourret, R, Bousquet, P, Braido, F, Brightling, CE, Brozek, J, Bucca, C, Buhl, R, Buonaiuto, R, Panaitescu, C, Cabanas, MTB, Burte, E, Bush, A, Caballero-Fonseca, F, Caillaud, D, Caimmi, D, Calderon, MA, Camargos, PAM, Camuzat, T, Canfora, G, Canonica, GW, Carlsen, KH, Carreiro-Martins, P, Carriazo, AM, Carr, W, Cartier, C, Casale, T, Castellano, G, Cepeda, AM, Chavannes, NH, Chen, Y, Chiron, R, Chivato, T, Chkhartishvili, E, Chuchalin, AG, Chung, KF, Ciaravolo, MM, Ciceran, A, Ciprandi, G, Coehlo, ACC, Colas, L, Colgan, E, Coll, J, Conforti, D, De Sousa, JC, Cortes-Grimaldo, RM, Corti, F, Mc Costa-Dominguez, Al Courbis, Cox, L, Crescenzo, M, Custovic, A, Dahlen, SE, D'Amato, Dario, C, da Silva, J, Dauvilliers, Y, Darsow, U, De Blay, F, De Carlo, G, Dedeu, T, Emerson, MDF, De Martino, B, Rubina, NPM, Deleanu, D, Demoly, P, Denburg, J, Ercolano, SDC, Di Carluccio, N, Didier, A, Dokic, D, Dominguez-Silva, MG, Douagui, H, Dray, G, Dubakiene, R, Durham, SR, Du Toit, G, Dykewicz, MS, El-Gamal, Y, Eklund, P, Emuzyte, R, Farrell, J, Farsi, A, De Mello, JF, Ferrero, J, Fink-Wagner, A, Fiocchi, A, Fok-Kens, WJ, Forti, S, Fuentes-Perez, JM, Galvez-Romero, JL, Gamkrelidze, A, Garcia-Aymerich, J, Garcia-Cobas, CY, Garcia-Cruz, MH, Genova, S, Christoff, G, Gereda, JE, Van Wijk, RG, Gomez, RM, Gomez-Vera, J, Diaz, SG, Gotua, M, Grisle, I, Guidacci, M, Guldemond, N, Gutter, Z, Guzman, M, Hajjam, J, Hernandez, L, Houri-Hane, J, Huerta-Villalobos, YR, Humbert, M, Iaccarino, G, Illario, M, Ispayeva, Z, Jares, E, Jassem, E, Johnston, SL, Joos, G, Jung, KS, Just, J, Jutel, M, Kaidashev, I, Kalyoncu, AF, Karjalainen, J, Kardas, P, Keith, PK, Khaitov, M, Khaltaev, N, Kleine-Tebbe, J, Kowalski, ML, Kuitunen, M, Kull, I, Kupczyk, M, Krzych-Falta, E, Lacwik, P, Lauri, D, Lavrut, J, L, TT, Lessa, M, Levato, G, Li, J, Lieberman, P, Liplec, A, Lipworth, B, Carlsen, KCL, Louis, R, Lourenco, O, Luna-Pech, JA, Magnan, A, Mahboub, B, Maier, D, Majer, I, Mandajieva, E, Manning, P, Keenoy, EDM, Marshall, GD, Masjedi, MR, Maspero, JF, Mathieu-Dupas, E, Campos, JJM, Al Matos, Maurer, M, Mavale-Manuel, S, Mayora, O, Medina-Avalos, MA, Melo-Gomes, E, Meltzer, E, Mercier, J, Miculinic, N, Mihaltan, F, Milenkovic, B, Moda, G, Mogica-Martinez, MD, Mohammad, Y, Momas, I, Monte-Fort, S, Monti, R, Bogado, DM, Morato-Castro, Mota-Pinto, A, Santo, PM, Munter, L, Muraro, A, Murray, R, Naclerio, R, Nadif, R, Nalin, M, Napoli, L, Namazova-Baranova, L, Neffen, H, Niedeberger, V, Nekam, K, Neou, A, Nieto, A, Nogueira-Silva, L, Nogues, M, Nyembue, T, O'Hehir, R, Odzhakova, C, Ohta, K, Okamoto, Y, Okubo, K, Onorato, GL, Cisneros, MO, Ouedraogo, S, Pali-Scholl, I, Palkonen, S, Panzner, P, Park, HS, Papi, A, Passalacqua, G, Paulino, E, Pawankar, R, Pedersen, S, Pepin, JL, Persico, M, Phillips, J, Picard, R, Pigearias, B, Pin, I, Pitsios, C, Plavec, D, Pohl, W, Popov, TA, Portejoie, F, Potter, P, Pozzi, AC, Price, D, Puy, R, Pugin, B, Ross, REP, Przemecka, M, Rabe, KF, Raciborski, F, Raja-Bian-Soderlund, R, Ribeirinho, I, Rimmer, J, Riv-Ero-Yeverino, D, Rizzo, JA, Rizzo, MC, Robalo-Cordeiro, C, Rodenas, F, Rodo, X, Gonzalez, MR, Rodriguez-Manas, L, Rolland, C, Valle, SR, Rodriguez, MR, Romano, A, Rodriguez-Zagal, E, Rolla, G, Romano, M, Rosado-Pinto, J, Rosario, N, Rottem, M, Sagara, H, Salimaki, J, Sanchez-Borges, M, Sastre-Dominguez, J, Scadding, GK, Schunemann, HJ, Scichilone, N, Schmid-Grendelmeier, P, Serpa, FS, Shamai, S, Sierra, M, Simons, FER, Sir-Oux, V, Sisul, JC, Skrindo, I, Sole, D, Somekh, D, Sonder-Mann, M, Sooronbaev, T, Sova, M, Sorensen, M, Sorlini, M, Spranger, O, Stelmach, R, Stukas, R, Sunyer, J, Strozek, J, Szylling, A, Tebyrica, J, Thibaudon, M, To, T, Todo-Bom, A, Trama, U, Triggiani, M, Ulrik, CS, Urrutia-Pereira, M, Valenta, R, Valero, A, Valovirta, E, Van Eerd, M, Van Ganse, E, Van Hague, M, Vandenplas, O, Ventura, MT, Vezzani, G, Vasankari, T, Vatrella, A, Verissimo, MT, Viart, F, Viegi, G, Vicheva, D, Vontetsianos, T, Wagenmann, M, Walker, S, Wallace, D, Wang, DY, Waserman, S, Werfel, T, Westman, M, Williams, DM, Williams, S, Wilson, N, Wright, J, Wroczynski, P, Yakovliev, P, Yawn, BP, Yiallouros, PK, Yorgancioglu, A, Yusuf, OM, Zar, HJ, Zhang, L, Zhong, N, Zernotti, ME, Zhanat, I, Zidarn, M, Zubrinich, C, Zurkuhlen, A, MASK Grp, İÜC, Cerrahpaşa Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü, Department of Dermatology, Allergology and Venereology, University of Helsinki, Clinicum, Children's Hospital, HUS Children and Adolescents, HUS Inflammation Center, et. al., Universidade do Minho, Internal Medicine, Health Services Management & Organisation (HSMO), Ear, Nose and Throat, AII - Inflammatory diseases, Kyomed, Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Università degli Studi di Salerno (UNISA), Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto, Institute of Medical Statistics, Informatics and Epidemiology (IMSIE), University of Cologne, Department of Otorhinolaryngology, Head, and Neck Surgery, University Hospital Leuven, Institute of Environmental Medicine, Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Astrid Lindgren Children's Hospital, Department of Allergy, Immunology and Respiratory Medicine, Alfred Hospital-Monash University Building, AMREP, Cerrahpasa Faculty of Medicine, Istanbul University, Hacettepe University = Hacettepe Üniversitesi, Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Department for Molecular Biomedical Research, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), CHU Montpellier, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Università degli Studi di Firenze = University of Florence [Firenze] (UNIFI), Department of Otorhinolaryngology, Head and Neck Surgery, Eskisehir Osmangazi University, Instituto de Biologia Molecular e Celular (IBMC), Laboratoire de Génie Informatique et d'Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), UCB Pharma, Colombes, Laboratoire de recherche sur les mécanismes moléculaires et pharmacologiques de l’obstruction bronchique (LOBIP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Department of Dermatology and Allergy Centre, Odense University Hospital, Department of Dermatology, Helsinki University Hospital-Skin and Allergy Hospital, Institute of Social Medicine, Epidemiology and Health Economics-Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], German Society for Otorhinolaryngology HNS, Medical University of Łódź (MUL), Vilnius University [Vilnius], Institut de Recherche en Infectiologie de Montpellier (IRIM), Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), University of Coimbra [Portugal] (UC), 'Federico II' University of Naples Medical School, Transverse group for research in primary care [Barcelona], Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Naples Federico II, University Hospital Mannheim, Allergy and Respiratory Research Group, University of Edinburgh, Department of Prevention of Envinronmental Hazards and Allergology, Medical University of Warsaw - Poland, Asthma UK Centre for Applied Research [Edinburgh, U.K.], University of Edinburgh-Usher Institute of Population Health Sciences and Informatics [Edinburgh, U.K.], Vilnius University Clinic of Children's Diseases, Sachs’ Children and Youth Hospital [Stockholm, Sweden], Secretary General of the Global Allergy and Asthma European Network (GA2LEN), Charité - UniversitätsMedizin = Charité - University Hospital [Berlin], Menditto, E, Costa, E, Midão, L, Bosnic-Anticevich, S, Novellino, E, Bialek, S, Briedis, V, Mair, A, Rajabian-Soderlund, R, Arnavielhe, S, Bedbrook, A, Czarlewski, W, Annesi-Maesano, I, Anto, Jm, Devillier, P, De Vries, G, Keil, T, Sheikh, A, Orlando, V, Larenas-Linnemann, D, Cecchi, L, De Feo, G, Illario, M, Stellato, C, Fonseca, J, Malva, J, Morais-Almeida, M, Pereira, Am, Todo-Bom, A, Kvedariene, V, Valiulis, A, Bergmann, Kc, Klimek, L, Mösges, R, Pfaar, O, Zuberbier, T, Cardona, V, Mullol, J, Papadopoulos, Ng, Prokopakis, Ep, Bewick, M, Ryan, D, Roller-Wirnsberger, Re, Tomazic, Pv, Cruz, Aa, Kuna, P, Samolinski, B, Fokkens, Wj, Reitsma, S, Bosse, I, Fontaine, Jf, Laune, D, Haahtela, T, Toppila-Salmi, S, Bachert, C, Hellings, Pw, Melén, E, Wickman, M, Bindslev-Jensen, C, Eller, E, O'Hehir, Re, Cingi, C, Gemicioğlu, B, Kalayci, O, Ivancevich, Jc, Bousquet, J, and Iaccarino, Guido
- Subjects
0301 basic medicine ,Male ,Allergy ,Medicina Básica [Ciências Médicas] ,CONTROLLER MEDICATION ,adherence ,mHealth ,mobile technology ,observational study ,rhinitis ,treatment ,THERAPY ,Medical and Health Sciences ,Medical Records ,DISEASE ,0302 clinical medicine ,Surveys and Questionnaires ,Immunology and Allergy ,Middle Aged ,Mobile Applications ,3. Good health ,Medication possession ratio ,rhiniti ,1107 Immunology ,Ciências Médicas::Medicina Básica ,Female ,TRIAL ,Life Sciences & Biomedicine ,Adult ,medicine.medical_specialty ,Immunology ,K-ANONYMITY ,VALIDATION ,1117 Public Health and Health Services ,Medication Adherence ,03 medical and health sciences ,Internal medicine ,Health Sciences ,medicine ,Humans ,Clinical significance ,Mobile technology ,[INFO]Computer Science [cs] ,Asthma ,Aged ,[SDV.EE.SANT]Life Sciences [q-bio]/Ecology, environment/Health ,Science & Technology ,Relative efficacy ,business.industry ,PERSISTENCE ,medicine.disease ,Rhinitis, Allergic ,Cell Phone Use ,Patient Outcome Assessment ,030104 developmental biology ,Cross-Sectional Studies ,030228 respiratory system ,3121 General medicine, internal medicine and other clinical medicine ,MASK group ,ASTHMA ,Observational study ,business - Abstract
Pereira, Ana Margarida/0000-0002-5468-0932; Briedis, Vitalis/0000-0002-5106-6638; Johnston, Sebastian Lennox/0000-0003-3009-9200; Orlando, Valentina/0000-0002-8209-8878; Sova, Milan/0000-0002-8542-7841; Chung, Kian Fan/0000-0001-7101-1426; Ciprandi, Giorgio/0000-0001-7016-8421; Yusuf, M Osman/0000-0002-8067-1204; stelmach, rafael/0000-0002-5132-1934; Sunyer, Jordi/0000-0002-2602-4110; Martins, Pedro/0000-0002-4129-133X; Demoly, Pascal/0000-0001-7827-7964; Fonseca, Joao Almeida/0000-0002-0887-8796; Anto, J M/0000-0002-4736-8529; IACCARINO, Guido/0000-0002-8997-835X; Custovic, Adnan/0000-0001-5218-7071; Lourenco, Olga/0000-0002-8401-5976; Pugin, Benoit/0000-0001-7132-9477; Chavannes, Niels/0000-0002-8607-9199; Rodo, Xavier/0000-0003-4843-6180; Nadif, Rachel/0000-0003-4938-9339; Plavec, Davor/0000-0003-2020-8119; Vicheva, Dilyana/0000-0002-6805-3825; Iaccarino, Guido/0000-0002-8997-835X; Annesi-Maesano, Isabella/0000-0002-6340-9300; N.G., Papadopoulos/0000-0002-4448-3468; J, Garcia-Aymerich/0000-0002-7097-4586; Humbert, Marc/0000-0003-0703-2892; Barbara, C./0000-0003-0915-4105; Gemicioglu, Bilun/0000-0001-5953-4881; Caimmi, Davide/0000-0003-4481-6194; Namazova-Baranova, Leyla/0000-0002-2209-7531; Basagana, Xavier/0000-0002-8457-1489; Midao, Luis/0000-0003-1981-2554; Sheikh, Aziz/0000-0001-7022-3056; O'Hehir, Robyn/0000-0002-3489-7595; Cardona, Victoria/0000-0003-2197-9767; Mota-Pinto, Anabela/0000-0002-0820-9568; Cecchi, Lorenzo/0000-0002-0658-2449; Bindslev-Jensen, Carsten/0000-0002-8940-038X; Costa, Elisio/0000-0003-1158-1480; Kuna, Piotr/0000-0003-2401-0070; Malva, Joao/0000-0002-5438-4447; Zuberbier, Torsten/0000-0002-1466-8875; Toppila-Salmi, Sanna/0000-0003-0890-6686; Nogueira-Silva, Luis/0000-0002-5519-707X; Ivancevich, Juan Carlos/0000-0001-8713-6258 WOS:000463761700007 PubMed ID: 30597673 Background: Mobile technology may help to better understand the adherence to treatment. MASK-rhinitis (Mobile Airways Sentinel NetworK for allergic rhinitis) is a patient-centred ICT system. A mobile phone app (the Allergy Diary) central to MASK is available in 22 countries. Objectives: To assess the adherence to treatment in allergic rhinitis patients using the Allergy Diary App. Methods: An observational cross-sectional study was carried out on all users who filled in the Allergy Diary from 1 January 2016 to 1 August 2017. Secondary adherence was assessed by using the modified Medication Possession Ratio (MPR) and the Proportion of days covered (PDC) approach. Results: A total of 12143 users were registered. A total of 6949 users reported at least one VAS data recording. Among them, 1887 users reported >= 7 VAS data. About 1195 subjects were included in the analysis of adherence. One hundred and thirty-six (11.28%) users were adherent (MPR >= 70% and PDC = 70% and PDC = 1.50) and 176 (14.60%) were switchers. On the other hand, 832 (69.05%) users were non-adherent to medications (MPR
- Published
- 2019
4. ARIA pharmacy 2018 'Allergic rhinitis care pathways for community pharmacy'
- Author
-
Bosnic-Anticevich S, Costa E, Menditto E, Lourenço O, Novellino E, Bialek S, Briedis V, Buonaiuto R, Chrystyn H, Cvetkovski B, Capua SD, Kritikos V, Mair A, Orlando V, Paulino E, Salimäki J, Söderlund R, Tan R, Williams DM, Wroczynski P, Agache I, Ansotegui IJ, Anto JM, Bedbrook A, Bachert C, Bewick M, Bindslev-Jensen C, Brozek J, Canonica GW, Cardona V, Carr W, Casale T, Chavannes NH, Correia de Sousa J, Cruz AA, Czarlewski W, De Carlo G, Demoly P, Devillier P, Dykewicz MS, Gaga M, El-Gamal Y, Fonseca J, Fokkens WJ, Guzmán MA, Haahtela T, Hellings PW, Illario M, Ivancevich JC, Just J, Kaidashev I, Khaitov M, Khaltaev N, Keil T, Klimek L, Kowalski ML, Kuna P, Kvedariene V, Larenas-Linnemann D, Laune D, Le LTT, Carlsen KCL, Mahboub B, Maier D, Malva J, Manning P, Morais-Almeida M, Mösges R7, Mullol J, Münter L, Murray R, Naclerio R, Namazova-Baranova L, Nekam K, Nyembue TD, Okubo K, O'Hehir RE, Ohta K, Okamoto Y, Onorato GL, Palkonen S, Panzner P, Papadopoulos NG, Park HS, Pawankar R, Pfaar O, Phillips J, Plavec D, Popov TA, Potter P, Prokopakis EP, Roller-Wirnsberger RE, Rottem M, Ryan D, Samolinski B, Sanchez-Borges M, Schunemann HJ, Sheikh A, Sisul JC, Somekh D, Stellato C, To T, Todo-Bom A, Tomazic PV, Toppila-Salmi S, Valero A, Valiulis A, Valovirta E, Ventura MT, Wagenmann M, Wallace D, Waserman S, Wickman M, Yiallouros PK, Yorgancioglu A, Yusuf OM, Zar HJ, Zernotti ME, Zhang L, Zidarn M, Zuberbier T, Bousquet J., Universidade do Minho, Bosnic-Anticevich, S, Costa, E, Menditto, E, Lourenço, O, Novellino, E, Bialek, S, Briedis, V, Buonaiuto, R, Chrystyn, H, Cvetkovski, B, Capua, Sd, Kritikos, V, Mair, A, Orlando, V, Paulino, E, Salimäki, J, Söderlund, R, Tan, R, Williams, Dm, Wroczynski, P, Agache, I, Ansotegui, Ij, Anto, Jm, Bedbrook, A, Bachert, C, Bewick, M, Bindslev-Jensen, C, Brozek, J, Canonica, Gw, Cardona, V, Carr, W, Casale, T, Chavannes, Nh, Correia de Sousa, J, Cruz, Aa, Czarlewski, W, De Carlo, G, Demoly, P, Devillier, P, Dykewicz, M, Gaga, M, El-Gamal, Y, Fonseca, J, Fokkens, Wj, Guzmán, Ma, Haahtela, T, Hellings, Pw, Illario, M, Ivancevich, Jc, Just, J, Kaidashev, I, Khaitov, M, Khaltaev, N, Keil, T, Klimek, L, Kowalski, Ml, Kuna, P, Kvedariene, V, Larenas-Linnemann, D, Laune, D, Le, Ltt, Carlsen, Kcl, Mahboub, B, Maier, D, Malva, J, Manning, P, Morais-Almeida, M, Mösges, R7, Mullol, J, Münter, L, Murray, R, Naclerio, R, Namazova-Baranova, L, Nekam, K, Nyembue, Td, Okubo, K, O'Hehir, Re, Ohta, K, Okamoto, Y, Onorato, Gl, Palkonen, S, Panzner, P, Papadopoulos, Ng, Park, H, Pawankar, R, Pfaar, O, Phillips, J, Plavec, D, Popov, Ta, Potter, P, Prokopakis, Ep, Roller-Wirnsberger, Re, Rottem, M, Ryan, D, Samolinski, B, Sanchez-Borges, M, Schunemann, Hj, Sheikh, A, Sisul, Jc, Somekh, D, Stellato, C, To, T, Todo-Bom, A, Tomazic, Pv, Toppila-Salmi, S, Valero, A, Valiulis, A, Valovirta, E, Ventura, Mt, Wagenmann, M, Wallace, D, Waserman, S, Wickman, M, Yiallouros, Pk, Yorgancioglu, A, Yusuf, Om, Zar, Hj, Zernotti, Me, Zhang, L, Zidarn, M, Zuberbier, T, and Bousquet, J.
- Subjects
ARIA ,Science & Technology ,Care pathways ,education ,Asthma ,care pathways ,pharmacist ,rhinitis ,Pharmacist ,care pathway ,Allergic Rhinitis and its Impact on Asthma ,Rhinitis - Abstract
Pharmacists are trusted health professionals. Many patients use over-the-counter (OTC) medications and are seen by pharmacists who are the initial point of contact of allergic rhinitis management in most countries. The role of pharmacists in integrated care pathways (ICPs) for allergic diseases is important. This paper builds on existing studies and provides tools intended to help pharmacists provide optimal advice/interventions/strategies to patients with rhinitis. The ARIA-pharmacy ICP includes a diagnostic questionnaire specifically focusing attention on key symptoms and markers of the disease, a systematic Diagnosis Guide (including differential diagnoses) and a simple flowchart with proposed treatment for rhinitis and asthma multimorbidity. Key prompts for referral within the ICP are included. The use of technology is critical to enhance the management of AR. However, the ARIA-pharmacy ICP should be adapted to local health care environments/situations as regional (national) differences exist in pharmacy care. This article is protected by copyright. All rights reserved., (undefined), info:eu-repo/semantics/acceptedVersion
- Published
- 2019
5. Fibrous histiocytoma in the far lateral frontal sinus
- Author
-
Kiss, P, additional, Wolf, A, additional, Andrianakis, A, additional, Holzmeister, C, additional, Weiland, T, additional, Hirsch, T, additional, Moser, U, additional, and Tomazic, PV, additional
- Published
- 2021
- Full Text
- View/download PDF
6. Angle between anterior and medial maxillary sinus wall is an additional predictive factor for enhanced visibility during pre-lacrimal window approach
- Author
-
Hirsch, T, additional, Andrianakis, A, additional, Holzmeister, C, additional, Moser, U, additional, Kiss, P, additional, Wolf, A, additional, Redzic, A, additional, and Tomazic, PV, additional
- Published
- 2021
- Full Text
- View/download PDF
7. Reflux symptom index and clinical laryngopharyngeal reflux as predictors for snoring and obstructive sleep apnoea
- Author
-
Holzmeister, C, additional, Andrianakis, A, additional, Kiss, P, additional, Moser, U, additional, Wolf, A, additional, and Tomazic, PV, additional
- Published
- 2021
- Full Text
- View/download PDF
8. Der Winkel zwischen anteriorer und medialer Kieferhöhlenwand als explorativer/prädiktiver Einflussfaktor im Rahmen des prelacrimal window approach
- Author
-
Hirsch, T, additional, Andrianakis, A, additional, Holzmeister, C, additional, Moser, U, additional, Kiss, P, additional, Wolf, A, additional, Redzic, A, additional, and Tomazic, PV, additional
- Published
- 2021
- Full Text
- View/download PDF
9. Vergleich der 3D-Endoskopie mit der 2D-Endoskopie im Rahmen von Eingriffen an den Nasennebenhöhlen
- Author
-
Treccosti, A, additional, Tomazic, PV, additional, Briner, HR, additional, Leunig, A, additional, Hoffmann, T, additional, and Sommer, F, additional
- Published
- 2021
- Full Text
- View/download PDF
10. Comparison of 3D endoscopy with 2D endoscopy in sinus surgery
- Author
-
Treccosti, A, additional, Tomazic, PV, additional, Briner, HR, additional, Leunig, A, additional, Hoffmann, T, additional, and Sommer, F, additional
- Published
- 2021
- Full Text
- View/download PDF
11. Correlation between work impairment, scores of rhinitis severity and asthma using the MASK-air ® App
- Author
-
Bédard, Annabelle, Antó, Josep, Fonseca, Joao, Arnavielhe, Sylvie, Bachert, Claus, Bedbrook, Anna, Bindslev-Jensen, Carsten, Bosnic-Anticevich, Sinthia, Cardona, Victoria, Cruz, Alvaro, Fokkens, Wytske, Garcia-Aymerich, Judith, Hellings, Peter, Ivancevich, Juan, Klimek, Ludger, Kuna, Piotr, Kvedariene, Violeta, Larenas-Linnemann, Désirée, Melen, Erik, Monti, Ricardo, Mösges, Ralf, Mullol, Joaquim, Papadopoulos, Nikos, Pham-Thi, Nhan, Samolinski, Boleslaw, V Tomazic, Peter, Toppila-Salmi, Sanna, Ventura, Maria Teresa, Yorgancioglu, Arzu, Bousquet, Jean, Pfaar, Oliver, Basagana, Xavier, Bosnic‐Anticevich, Sinthia, Pham‐Thi, Nhân, Hellings, PW, Aberer, W., Agache, I., Akdis, Ca, Akdis, M., Aliberti, MR, Almeida, R., Amat, F., Angles, R, Annesi‐Maesano, I, Ansotegui, IJ, Anto, JM, Arnavielle, S, Asayag, E, Asarnoj, A, Arshad, H, Avolio, F, Bacci, E, Baiardini, I, Barbara, C, Barbagallo, M., Baroni, I, Barreto, BA, Basagaña, X., Bateman, ED, Bedolla‐Barajas, M, Bewick, M., Beghé, B., Bel, EH, Bergmann, KC, Bennoor, KS, Benson, M, Bertorello, L, Białoszewski, AZ, Bieber, T., Bialek, S, Bindslev‐Jensen, Carsten, Bjermer, L., Blain, H., Blasi, F., Blua, A, Bochenska Marciniak, M, Bogus‐Buczynska, I, Boner, AL, Bonini, M., Bonini, S., Bosnic‐Anticevich, CS, Bosse, I., Bouchard, J., Boulet, LP, Bourret, R., Bousquet, Pj, Braido, F, Briedis, V, Brightling, CE, Brozek, J, Bucca, C, Buhl, R, Buonaiuto, R, Panaitescu, C, Burguete Cabañas, MT, Burte, E., Bush, A, Caballero‐Fonseca, F, Caillaud, D., Caimmi, D., Calderon, MA, Camargos, PAM, Camuzat, T., Canfora, G, Canonica, Gw, Carlsen, KH, Carreiro‐Martins, P, Carriazo, AM, Carr, W, Cartier, C., Casale, T., Castellano, G, Cecchi, L, Cepeda, AM, Chavannes, NH, Chen, Y., Chiron, R., Chivato, T, Chkhartishvili, E, Chuchalin, AG, Chung, KF, Ciaravolo, MM, Ciceran, A, Cingi, C, Ciprandi, G, Carvalho Coehlo, AC, Colas, L, Colgan, E, Coll, J, Conforti, D, Constantinidis, J, de Sousa, J Correia, Cortés‐Grimaldo, RM, Corti, F, Costa, E, Costa‐Dominguez, MC, Courbis, AL, Cox, L, Crescenzo, M, Cruz, AA, Custovic, A., Czarlewski, W., Dahlen, Se, D’Amato, G, Dario, C, Da Silva, J., Dauvilliers, Y., Darsow, U, De Blay, F., De Carlo, G, Dedeu, T, de Fátima Emerson, M, De Feo, G., De Vries, G, De Martino, B, Motta Rubini, NP, Deleanu, D, Denburg, JA, devillier, P., Di Capua Ercolano, S, Di Carluccio, N, Didier, A., Dokic, D, Dominguez‐Silva, MG, Douagui, H, Dray, G., Dubakiene, R, Durham, Sr, Du Toit, G, Dykewicz, MS, El‐Gamal, Y, Eklund, P, Eller, E, Emuzyte, R., Farrell, J, Farsi, A, de Mello, J Ferreira, Ferrero, J, Fink‐Wagner, A, Fiocchi, A, Fokkens, WJ, Fonseca, JA, Fontaine, Jf, Forti, S, Fuentes‐Perez, JM, Gálvez‐Romero, JL, Gamkrelidze, A, Garcia‐Aymerich, Judith, García‐Cobas, CY, Garcia‐Cruz, MH, Gemicioğlu, B, Genova, S, Christoff, G, Gereda, JE, Van Wijk, R Gerth, Gomez, RM, Gómez‐Vera, J, González Diaz, S, Gotua, M., Grisle, I, Guidacci, M, Guldemond, NA, Gutter, Z, Guzmán, MA, Haahtela, T., Hajjam, J, Hernández, L, Hourihane, JO’B, Huerta‐Villalobos, YR, Humbert, M., Iaccarino, G., Illario, M, Ispayeva, Z, Ivancevich, JC, Jares, EJ, Jassem, E, Johnston, Sl, Joos, G, Jung, KS, Just, J., Jutel, M, Kaidashev, I, Kalayci, O, Kalyoncu, AF, Karjalainen, J, Kardas, P, Keil, T, Keith, PK, Khaitov, M, Khaltaev, N, Kleine‐Tebbe, J, Kowalski, Ml, Kuitunen, M, Kull, I., Kupczyk, M, Krzych‐Fałta, E, Lacwik, P, Larenas‐Linnemann, Désirée, Laune, D., Lauri, D, Lavrut, J, Le, LTT, Lessa, M, Levato, G, Li, J., Lieberman, P, Lipiec, A, Lipworth, B, Lodrup Carlsen, KC, Louis, R, Lourenço, O, Luna‐Pech, JA, Magnan, A., Mahboub, B, Maier, D., Mair, A, Majer, I, Malva, J, Mandajieva, E, Manning, P, De Manuel Keenoy, E, Marshall, GD, Masjedi, MR, Maspero, JF, Mathieu‐Dupas, E, Matta Campos, JJ, Matos, AL, Maurer, M, Mavale‐Manuel, S, Mayora, O, Meco, C, Medina‐Avalos, MA, Melo‐Gomes, E, Meltzer, EO, Menditto, E., Miculinic, N, Mihaltan, F., Milenkovic, B, Moda, G, Mogica‐Martinez, MD, Mohammad, Y, Momas, I., Montefort, S, Mora Bogado, D, Morais‐Almeida, M, Morato‐Castro, FF, Mota‐Pinto, A, Moura Santo, P, Münter, L, Muraro, A, Murray, R, Naclerio, R., Nadif, R., Nalin, M, Napoli, L, Namazova‐Baranova, L, Neffen, H, Niedeberger, V, Nekam, K, Neou, A, Nieto, A, Nogueira‐Silva, L, Nogues, M., Novellino, E, Nyembue, TD, O’Hehir, RE, Odzhakova, C, Ohta, K., Okamoto, Y., Okubo, K, Onorato, GL, Ortega Cisneros, M, Ouédraogo, S., Pali‐Schöll, I, Palkonen, S, Panzner, P, Papadopoulos, NG, Park, HS, Papi, A., Passalacqua, G, Paulino, E, Pawankar, R, Pedersen, S, Pépin, JL, Pereira, AM, Persico, M, PHILLIPS, J, Picard, R., Pigearias, B, Pin, I., Pitsios, C., Plavec, D, Pohl, W, Popov, TA, Portejoie, F., Potter, P, Pozzi, AC, Price, D, Prokopakis, EP, Puy, R, Pugin, B, Pulido Ross, RE, Przemecka, M, Rabe, KF, Raciborski, F, Rajabian‐Soderlund, R, Reitsma, S, Ribeirinho, I, Rimmer, J, Rivero‐Yeverino, D, Rizzo, JA, Rizzo, MC, Robalo‐Cordeiro, C, Rodenas, F, Rodo, X, Rodriguez Gonzalez, M, Rodriguez‐Mañas, L, Rolland, C, Rodrigues Valle, S, Roman Rodriguez, M., Romano, A, Rodriguez‐Zagal, E, Rolla, G, Roller‐Wirnsberger, RE, Romano, M, Rosado‐Pinto, J, Rosario, N., Rottem, M, Ryan, D, Sagara, H, Salimäki, J, Sanchez‐Borges, M, Sastre‐Dominguez, J, Scadding, GK, Schunemann, HJ, Scichilone, N, Schmid‐Grendelmeier, P, Sarquis Serpa, F, Shamai, S., Sheikh, A., Sierra, M, Simons, FER, Siroux, V., Sisul, JC, Skrindo, I, Solé, D, Somekh, D, Sondermann, M, Sooronbaev, T, Sova, M, Sorensen, M, Sorlini, M, Spranger, O, Stellato, C, Stelmach, R, Stukas, R, Sunyer, J., Strozek, J, Szylling, A, Tebyriçá, JN, Thibaudon, M., To, T., Todo‐Bom, A, Tomazic, PV, Toppila‐Salmi, Sanna, Trama, U, Triggiani, M, Suppli Ulrik, C, Urrutia‐Pereira, M, Valenta, R, Valero, A., Valiulis, A., Valovirta, E., van Eerd, M, Van Ganse, E., van Hage, M, Vandenplas, O, Ventura, MT, Vezzani, G, Vasankari, T, Vatrella, A., Verissimo, MT, Viart, F., Viegi, G., Vicheva, D, Vontetsianos, T, Wagenmann, M, Walker, S, Wallace, D, Wang, DY, Waserman, S., Werfel, T, Westman, M, Wickman, M., Williams, DM, Williams, S, Wilson, N, Wright, J, Wroczynski, P, Yakovliev, P, Yawn, BP, Yiallouros, PK, Yusuf, OM, Zar, HJ, Zhang, L., Zhong, N, Zernotti, ME, Zhanat, I, Zidarn, M, Zuberbier, T., Zubrinich, C, Zurkuhlen, A, Mercier, Jacques, Instituto de Salud Global - Institute For Global Health [Barcelona] (ISGlobal), Universitat Pompeu Fabra [Barcelona] (UPF), CIBER de Epidemiología y Salud Pública (CIBERESP), IMIM-Hospital del Mar, Generalitat de Catalunya, Center of Research in Health Technologies and Information Systems (CINTESIS), Universidade do Porto = University of Porto, KYomed INNOV, Ghent University Hospital, Contre les MAladies Chroniques pour un VIeillissement Actif en Languedoc-Roussillon (MACVIA-LR), Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO), Odense University Hospital [Odense, Denmark], Woolcock Institute of Medical Research [Sydney], The University of Sydney, Vall d'Hebron University Hospital [Barcelona], ProAR - FMB, Federal University of Bahia School of Medicine, European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA), University Hospitals Leuven [Leuven], Zentrum für Rhinologie und Allergologie [Wiesbaden, Germany], Division of Internal Medicine, Asthma and Allergy, Medical University of Łódź (MUL)-Barlicki University Hospital, Vilnius University [Vilnius], Clínica de Alergia- Asma y Pediatría, Hospital Medica Sur, Institute of Environmental Medicine, Karolinska Institutet [Stockholm]-Karolinska University Hospital [Stockholm]-Astrid Lindgren Children's Hospital, Centro de Investigación Biomédica en Red Enfermedades Respiratorias (CIBERES), Service de Pneumologie Allergologie [CHU Necker], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Necker - Enfants Malades [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Institut Pasteur [Paris] (IP), Medical University of Warsaw - Poland, Department of Pulmonology, Manisa Celal Bayar University, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Vieillissement et Maladies chroniques : approches épidémiologique et de santé publique (VIMA), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Institut National de la Santé et de la Recherche Médicale (INSERM), Center for Rhinology and Allergology Wiesbaden, University Hospital Mannheim, Center for Research in Environmental Epidemiology (CREAL), Universitat Pompeu Fabra [Barcelona] (UPF)-Catalunya ministerio de salud, Department of Allergy and Clinical Immunology, Faculty of Medicine-Transylvania University, Swiss Institute of Allergy and Asthma Research (SIAF), Universität Zürich [Zürich] = University of Zurich (UZH), Department Engineering Quimica (ICEMS), Aix Marseille Université (AMU), Istituto Nazionale di Fisica Nucleare, sezione di Bari (INFN, sezione di Bari), Istituto Nazionale di Fisica Nucleare (INFN), iQ4U consultants Ltd, Divisions of Human Genetics Infection, Inflammation and Repair, University of Southampton-School of Medicine, Department of Respiratory Medicine and Allergy, Department of Pathophysiology and Transplantation, Università degli Studi di Milano = University of Milan (UNIMI), Istituto di Geoscienze e Georisorse, Pavia, Institute of Neurobiology and Molecular Medicine, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II = Università degli studi di Napoli Federico II, CHU Montpellier, Laboratoire National Henri Becquerel (LNHB), Département Métrologie Instrumentation & Information (DM2I), Laboratoire d'Intégration des Systèmes et des Technologies (LIST (CEA)), Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Laboratoire d'Intégration des Systèmes et des Technologies (LIST (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Département d'instrumentation Numérique (DIN (CEA-LIST)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA), Unité de Nutrition Humaine (UNH), Université Clermont Auvergne [2017-2020] (UCA [2017-2020])-Institut National de Recherche pour l’Agriculture, l’Alimentation et l’Environnement (INRAE), Laboratoire de recherche sur les mécanismes moléculaires et pharmacologiques de l’obstruction bronchique (LOBIP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Région Languedoc-Roussillon-Midi-Pyrénées, University of South Florida [Tampa] (USF), Chinese academy of sciences Sanya, Centres de Ressources et de Compétences de la Mucoviscidose [Montpellier] (CRCM [Montpellier]), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Arnaud de Villeneuve-Service des Maladies Respiratoires, Laboratoire de Génie Informatique et d'Ingénierie de Production (LGI2P), IMT - MINES ALES (IMT - MINES ALES), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT), Department of Paediatrics, UCB Pharma, Colombes, CHU Strasbourg, Università degli Studi di Salerno = University of Salerno (UNISA), Hôpital Foch [Suresnes], Service de pneumologie [Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Informatique, Image, Intelligence Artificielle (I3A), Institut Mines-Télécom [Paris] (IMT)-Institut Mines-Télécom [Paris] (IMT)-IMT - MINES ALES (IMT - MINES ALES), Laboratoire Electronique, Informatique et Image [UMR6306] (Le2i), Université de Bourgogne (UB)-École Nationale Supérieure d'Arts et Métiers (ENSAM), Arts et Métiers Sciences et Technologies, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-HESAM Université - Communauté d'universités et d'établissements Hautes écoles Sorbonne Arts et métiers université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Center for Allergy and Immunology Research [Tbilisi], Helsingin yliopisto = Helsingfors universitet = University of Helsinki, Center for Turbulence Research [Stanford] (CTR), Stanford University, CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), The Institute of Environmental Medicine [Stockholm] (IMM), Karolinska Institutet [Stockholm], Sysdiag-Modélisation et Ingénierie des Systèmes Complexes Biologiques pour le Diagnostic (SysDiag ), BIO-RAD-Centre National de la Recherche Scientifique (CNRS), Équipe de Recherche en Textes, Informatique, Multilinguisme (ERTIM), Institut National des Langues et Civilisations Orientales (Inalco), Unité de recherche de l'institut du thorax (ITX-lab), Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS)-Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN), Biomax Informatics AG, 'Federico II' University of Naples Medical School, Pneumology Department, Marius Nasta Institute of Pneumology, Epidémiologie Environnementale : Impact Sanitaire des Pollutions (EA 4064), Université Paris Descartes - Paris 5 (UPD5), Johns Hopkins University School of Medicine [Baltimore], CARSAT-LR, Montpellier, Dept. of Electronic Engineering, Chubu University, Institute for Solid State Physics, The University of Tokyo (UTokyo), Respiratory Medicine, Laboratoire de physique et chimie des nano-objets (LPCNO), Institut National des Sciences Appliquées - Toulouse (INSA Toulouse), Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut National des Sciences Appliquées (INSA)-Université de Toulouse (UT)-Institut de Chimie de Toulouse (ICT), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), CHU Grenoble, University of Cyprus [Nicosia] (UCY), Son Pisa Primary Care Centre, IB-Salut Balearic Health Service, Department of Computer Science [Haifa], University of Haifa [Haifa], University of Edinburgh, Institute for Advanced Biosciences / Institut pour l'Avancée des Biosciences (Grenoble) (IAB), Centre Hospitalier Universitaire [Grenoble] (CHU)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Etablissement français du sang - Auvergne-Rhône-Alpes (EFS)-Centre National de la Recherche Scientifique (CNRS)-Université Grenoble Alpes (UGA), Réseau National de Surveillance Aérobiologique (RNSA), CIRCE, Ctr Res Energy Resources & Consumpt, Zaragoza 50018, Spain, University of Turku, Evaluation et modélisation des effets thérapeutiques, Département biostatistiques et modélisation pour la santé et l'environnement [LBBE], Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Université Claude Bernard Lyon 1 (UCBL), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS)-Laboratoire de Biométrie et Biologie Evolutive - UMR 5558 (LBBE), Université de Lyon-Université de Lyon-Institut National de Recherche en Informatique et en Automatique (Inria)-VetAgro Sup - Institut national d'enseignement supérieur et de recherche en alimentation, santé animale, sciences agronomiques et de l'environnement (VAS)-Centre National de la Recherche Scientifique (CNRS), ASA (Advanced Solution Accelerator) (Data management : Développement Back-Office, hébergement…), 34830 Jacou, Consiglio nazionale delle ricerche, Instituto di fisiologia clinica, McMaster University [Hamilton, Ontario], Department of Molecular Medicine and Surgery, UMR CNRS 8179, Université de Lille, Sciences et Technologies-Centre National de la Recherche Scientifique (CNRS), University Hospital of Cologne [Cologne], Physiologie & médecine expérimentale du Cœur et des Muscles [U 1046] (PhyMedExp), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS), ISGlobal, Barcelona, Spain, Universitat Pompeu Fabra (UPF), Barcelona, Spain, CIBER Epidemiología y Salud Pública (CIBERESP), Barcelona, Spain, IMIM (Hospital del Mar Research Institute), Barcelona, Spain, CINTESIS, Center for Research in Health Technology and Information Systems, Faculdade de Medicina da Universidade do Porto, Porto, Portugal, Medida, Lda Porto, Porto, Portugal, KYomed INNOV, Montpellier, France, Upper Airways Research Laboratory, ENT Dept, Ghent University Hospital, Ghent, Belgium, MACVIA-France, Montpellier, France, Department of Dermatology and Allergy Centre, Odense University Hospital, Odense Research Center for Anaphylaxis (ORCA), Odense, Denmark, Woolcock Institute of Medical Research, University of Sydney and Woolcock Emphysema Centre and Sydney Local Health District, Glebe, NSW, Australia, Allergy Section, Department of Internal Medicine, Hospital Vall d'Hebron & ARADyAL Research Network, Barcelona, Spain, ProAR – Nucleo de Excelencia em Asma, Federal University of Bahia, Brasil and WHO GARD Planning Group, Salvador, Brazil, Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, Netherlands, Euforea, Brussels, Belgium, Department of Otorhinolaryngology, University Hospitals Leuven, Leuven, Belgium, Academic Medical Center, University of Amsterdam, Amsterdam, Netherlands, Servicio de Alergia e Immunologia, Clinica Santa Isabel, Buenos Aires, Argentina, Center for Rhinology and Allergology, Wiesbaden, Germany, Division of Internal Medicine, Asthma and Allergy, Barlicki University Hospital, Medical University of Lodz, Lodz, Poland, Department of Pathology, Faculty of Medicine, Institute of Biomedical Sciences, Vilnius University, Vilnius, Lithuania, Clinic of Chest diseases and Allergology, Faculty of Medicine, Institute of Clinical Medicine, Vilnius, Lithuania, Center of Excellence in Asthma and Allergy, Médica Sur Clinical Foundation and Hospital, México City, Mexico, Sachs' Children and Youth Hospital, Södersjukhuset, Stockholm, Sweden, Institute of Environmental Medicine, Karolinska Institutet, Stockholm, Sweden, Allergy and Clinical Immunology Unit, Department of Medical Sciences, University of Torino & Mauriziano Hospital, Torino, Italy, Institute of Medical Statistics, and Computational Biology, Medical Faculty, University of Cologne, Cologne, Germany, CRI-Clinical Research International-Ltd, Hamburg, Germany, Rhinology Unit & Smell Clinic, ENT Department, Hospital Clínic, University of Barcelona, Barcelona, Spain, Clinical & Experimental Respiratory Immunoallergy, IDIBAPS, CIBERES, University of Barcelona, Barcelona, Spain, Division of Infection, Immunity & Respiratory Medicine, Royal Manchester Children's Hospital, University of Manchester, Manchester, United Kingdom, Allergy Department, Pasteur Institute, Paris, France, Department of Prevention of Environmental Hazards and Allergology, Medical University of Warsaw, Warsaw, Poland, Department of General ORL, H&NS, Medical University of Graz, Graz, Austria, Skin and Allergy Hospital, Helsinki University Hospital, and University of Helsinki, Helsinki, Finland, Unit of Geriatric Immunoallergology, University of Bari Medical School, Bari, Italy, Department of Pulmonary Diseases, Faculty of Medicine, Celal Bayar University, Manisa, Turkey, University Hospital, Montpellier, France, INSERM U 1168, VIMA: Ageing and Chronic Diseases Epidemiological and Public Health Approaches, Villejuif, France, UMR-S 1168, Université Versailles St-Quentin-en-Yvelines, Versailles, France, Charité, Universitätsmedizin Berlin, Humboldt-Universität zu Berlin, Berlin, Germany, Comprehensive Allergy Center, Department of Dermatology and Allergy, Berlin Institute of Health, Berlin, Germany, Department of Otorhinolaryngology, Head and Neck Surgery, Section of Rhinology and Allergy, University Hospital Marburg, Phillipps-Universität, Marburg, Germany, Universidade do Porto, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Université Montpellier 1 (UM1)-Centre Hospitalier Universitaire de Nîmes (CHU Nîmes)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Commission Européenne-Commission Européenne-Organisation Mondiale de la Santé / World Health Organization Office (OMS / WHO)-Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Institut Pasteur [Paris], University of Milan, University of Naples Federico II-CNR, Rome, Italy and Department of Medicine, Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay, Università degli Studi di Salerno (UNISA), CHU Toulouse [Toulouse]-Hôpital Larrey [Toulouse], CHU Toulouse [Toulouse], Université de Bourgogne (UB)-Centre National de la Recherche Scientifique (CNRS)-École Nationale Supérieure d'Arts et Métiers (ENSAM), HESAM Université (HESAM)-HESAM Université (HESAM)-Arts et Métiers Sciences et Technologies, HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement, University of Helsinki, Service d'Allergologie pédiatrique [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), unité de recherche de l'institut du thorax UMR1087 UMR6291 (ITX), Astrophysique Interprétation Modélisation (AIM (UMR_7158 / UMR_E_9005 / UM_112)), Centre National de la Recherche Scientifique (CNRS)-Institut national des sciences de l'Univers (INSU - CNRS)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris Diderot - Paris 7 (UPD7), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Centre National de la Recherche Scientifique (CNRS)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS), University of Cyprus [Nicosia], Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Bedard, A., Anto, J. M., Fonseca, J. A., Arnavielhe, S., Bachert, C., Bedbrook, A., Bindslev-Jensen, C., Bosnic-Anticevich, S., Cardona, V., Cruz, A. A., Fokkens, W. J., Garcia-Aymerich, J., Hellings, P. W., Ivancevich, J. C., Klimek, L., Kuna, P., Kvedariene, V., Larenas-Linnemann, D., Melen, E., Monti, R., Mosges, R., Mullol, J., Papadopoulos, N. G., Pham-Thi, N., Samolinski, B., Tomazic, P. V., Toppila-Salmi, S., Ventura, M. T., Yorgancioglu, A., Bousquet, J., Pfaar, O., Basagana, X., Aberer, W., Agache, I., Akdis, C. A., Akdis, M., Aliberti, M. R., Almeida, R., Amat, F., Angles, R., Annesi-Maesano, I., Ansotegui, I. J., Arnavielle, S., Asayag, E., Asarnoj, A., Arshad, H., Avolio, F., Bacci, E., Baiardini, I., Barbara, C., Barbagallo, M., Baroni, I., Barreto, B. A., Bateman, E. D., Bedolla-Barajas, M., Bewick, M., Beghe, B., Bel, E. H., Bergmann, K. C., Bennoor, K. S., Benson, M., Bertorello, L., Bialoszewski, A. Z., Bieber, T., Bialek, S., Bjermer, L., Blain, H., Blasi, F., Blua, A., Bochenska Marciniak, M., Bogus-Buczynska, I., Boner, A. L., Bonini, M., Bonini, S., Bosse, I., Bouchard, J., Boulet, L. P., Bourret, R., Bousquet, P. J., Braido, F., Briedis, V., Brightling, C. E., Brozek, J., Bucca, C., Buhl, R., Buonaiuto, R., Panaitescu, C., Burguete Cabanas, M. T., Burte, E., Bush, A., Caballero-Fonseca, F., Caillaud, D., Caimmi, D., Calderon, M. A., Camargos, P. A. M., Camuzat, T., Canfora, G., Canonica, G. W., Carlsen, K. H., Carreiro-Martins, P., Carriazo, A. M., Carr, W., Cartier, C., Casale, T., Castellano, G., Cecchi, L., Cepeda, A. M., Chavannes, N. H., Chen, Y., Chiron, R., Chivato, T., Chkhartishvili, E., Chuchalin, A. G., Chung, K. F., Ciaravolo, M. M., Ciceran, A., Cingi, C., Ciprandi, G., Carvalho Coehlo, A. C., Colas, L., Colgan, E., Coll, J., Conforti, D., Constantinidis, J., Correia de Sousa, J., Cortes-Grimaldo, R. M., Corti, F., Costa, E., Costa-Dominguez, M. C., Courbis, A. L., Cox, L., Crescenzo, M., Custovic, A., Czarlewski, W., Dahlen, S. E., D'Amato, G., Dario, C., da Silva, J., Dauvilliers, Y., Darsow, U., De Blay, F., De Carlo, G., Dedeu, T., de Fatima Emerson, M., De Feo, G., De Vries, G., De Martino, B., Motta Rubini, N. P., Deleanu, D., Denburg, J. A., Devillier, P., Di Capua Ercolano, S., Di Carluccio, N., Didier, A., Dokic, D., Dominguez-Silva, M. G., Douagui, H., Dray, G., Dubakiene, R., Durham, S. R., Du Toit, G., Dykewicz, M. S., El-Gamal, Y., Eklund, P., Eller, E., Emuzyte, R., Farrell, J., Farsi, A., Ferreira de Mello, J., Ferrero, J., Fink-Wagner, A., Fiocchi, A., Fontaine, J. F., Forti, S., Fuentes-Perez, J. M., Galvez-Romero, J. L., Gamkrelidze, A., Garcia-Cobas, C. Y., Garcia-Cruz, M. H., Gemicioglu, B., Genova, S., Christoff, G., Gereda, J. E., Gerth van Wijk, R., Gomez, R. M., Gomez-Vera, J., Gonzalez Diaz, S., Gotua, M., Grisle, I., Guidacci, M., Guldemond, N. A., Gutter, Z., Guzman, M. A., Haahtela, T., Hajjam, J., Hernandez, L., Hourihane, J. O. '. B., Huerta-Villalobos, Y. R., Humbert, M., Iaccarino, G., Illario, M., Ispayeva, Z., Jares, E. J., Jassem, E., Johnston, S. L., Joos, G., Jung, K. S., Just, J., Jutel, M., Kaidashev, I., Kalayci, O., Kalyoncu, A. F., Karjalainen, J., Kardas, P., Keil, T., Keith, P. K., Khaitov, M., Khaltaev, N., Kleine-Tebbe, J., Kowalski, M. L., Kuitunen, M., Kull, I., Kupczyk, M., Krzych-Falta, E., Lacwik, P., Laune, D., Lauri, D., Lavrut, J., Le, L. T. T., Lessa, M., Levato, G., Li, J., Lieberman, P., Lipiec, A., Lipworth, B., Lodrup Carlsen, K. C., Louis, R., Lourenco, O., Luna-Pech, J. A., Magnan, A., Mahboub, B., Maier, D., Mair, A., Majer, I., Malva, J., Mandajieva, E., Manning, P., De Manuel Keenoy, E., Marshall, G. D., Masjedi, M. R., Maspero, J. F., Mathieu-Dupas, E., Matta Campos, J. J., Matos, A. L., Maurer, M., Mavale-Manuel, S., Mayora, O., Meco, C., Medina-Avalos, M. A., Melo-Gomes, E., Meltzer, E. O., Menditto, E., Mercier, J., Miculinic, N., Mihaltan, F., Milenkovic, B., Moda, G., Mogica-Martinez, M. D., Mohammad, Y., Momas, I., Montefort, S., Mora Bogado, D., Morais-Almeida, M., Morato-Castro, F. F., Mota-Pinto, A., Moura Santo, P., Munter, L., Muraro, A., Murray, R., Naclerio, R., Nadif, R., Nalin, M., Napoli, L., Namazova-Baranova, L., Neffen, H., Niedeberger, V., Nekam, K., Neou, A., Nieto, A., Nogueira-Silva, L., Nogues, M., Novellino, E., Nyembue, T. D., O'Hehir, R. E., Odzhakova, C., Ohta, K., Okamoto, Y., Okubo, K., Onorato, G. L., Ortega Cisneros, M., Ouedraogo, S., Pali-Scholl, I., Palkonen, S., Panzner, P., Park, H. S., Papi, A., Passalacqua, G., Paulino, E., Pawankar, R., Pedersen, S., Pepin, J. L., Pereira, A. M., Persico, M., Phillips, J., Picard, R., Pigearias, B., Pin, I., Pitsios, C., Plavec, D., Pohl, W., Popov, T. A., Portejoie, F., Potter, P., Pozzi, A. C., Price, D., Prokopakis, E. P., Puy, R., Pugin, B., Pulido Ross, R. E., Przemecka, M., Rabe, K. F., Raciborski, F., Rajabian-Soderlund, R., Reitsma, S., Ribeirinho, I., Rimmer, J., Rivero-Yeverino, D., Rizzo, J. A., Rizzo, M. C., Robalo-Cordeiro, C., Rodenas, F., Rodo, X., Rodriguez Gonzalez, M., Rodriguez-Manas, L., Rolland, C., Rodrigues Valle, S., Roman Rodriguez, M., Romano, A., Rodriguez-Zagal, E., Rolla, G., Roller-Wirnsberger, R. E., Romano, M., Rosado-Pinto, J., Rosario, N., Rottem, M., Ryan, D., Sagara, H., Salimaki, J., Sanchez-Borges, M., Sastre-Dominguez, J., Scadding, G. K., Schunemann, H. J., Scichilone, N., Schmid-Grendelmeier, P., Sarquis Serpa, F., Shamai, S., Sheikh, A., Sierra, M., Simons, F. E. R., Siroux, V., Sisul, J. C., Skrindo, I., Sole, D., Somekh, D., Sondermann, M., Sooronbaev, T., Sova, M., Sorensen, M., Sorlini, M., Spranger, O., Stellato, C., Stelmach, R., Stukas, R., Sunyer, J., Strozek, J., Szylling, A., Tebyrica, J. N., Thibaudon, M., To, T., Todo-Bom, A., Trama, U., Triggiani, M., Suppli Ulrik, C., Urrutia-Pereira, M., Valenta, R., Valero, A., Valiulis, A., Valovirta, E., van Eerd, M., van Ganse, E., van Hage, M., Vandenplas, O., Vezzani, G., Vasankari, T., Vatrella, A., Verissimo, M. T., Viart, F., Viegi, G., Vicheva, D., Vontetsianos, T., Wagenmann, M., Walker, S., Wallace, D., Wang, D. Y., Waserman, S., Werfel, T., Westman, M., Wickman, M., Williams, D. M., Williams, S., Wilson, N., Wright, J., Wroczynski, P., Yakovliev, P., Yawn, B. P., Yiallouros, P. K., Yusuf, O. M., Zar, H. J., Zhang, L., Zhong, N., Zernotti, M. E., Zhanat, I., Zidarn, M., Zuberbier, T., Zubrinich, C., Zurkuhlen, A., HESAM Université (HESAM)-HESAM Université (HESAM)-AgroSup Dijon - Institut National Supérieur des Sciences Agronomiques, de l'Alimentation et de l'Environnement-Centre National de la Recherche Scientifique (CNRS), Université de Nantes - UFR de Médecine et des Techniques Médicales (UFR MEDECINE), Université de Nantes (UN)-Université de Nantes (UN)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Universitat Pompeu Fabra [Barcelona]-Catalunya ministerio de salud, Universidade do Porto [Porto], Kyomed, Université Montpellier 1 (UM1)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire de Nîmes (CHRU Nîmes)-Université de Montpellier (UM)-Centre National de la Recherche Scientifique (CNRS)-European Innovation Partnership on Active and Healthy Ageing Reference Site (EIP on AHA), Universitat Pompeu Fabra [Barcelona], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Necker - Enfants Malades [AP-HP], Service des Maladies Respiratoires, Hôpital Arnaud de Villeneuve-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Dermatology [Graz, Austria], Medical University Graz, University of Zürich [Zürich] (UZH), National Institute for Nuclear Physics (INFN), Institut Jean Lamour (IJL), Université de Lorraine (UL)-Centre National de la Recherche Scientifique (CNRS), Université Paris-Saclay-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Université Paris-Saclay-Direction de Recherche Technologique (CEA) (DRT (CEA)), Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Laboratoire d'Intégration des Systèmes et des Technologies (LIST), Clermont Université-Université d'Auvergne - Clermont-Ferrand I (UdA)-Institut National de la Recherche Agronomique (INRA), University of South Florida (USF), University of Salerno (UNISA), CHU Toulouse [Toulouse]-Hôpital Larrey, Institut Mines-Télécom [Paris] (IMT), Center for Turbulence Research (CTR), Stanford University [Stanford], Service d'allergologie [CHU Trousseau], Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-CHU Trousseau [APHP], Commissariat à l'énergie atomique et aux énergies alternatives (CEA)-Institut national des sciences de l'Univers (INSU - CNRS)-Université Paris Diderot - Paris 7 (UPD7)-Centre National de la Recherche Scientifique (CNRS), The University of Tokyo, Sondra, CentraleSupélec, Université Paris-Saclay (SONDRA), ONERA-CentraleSupélec-Université Paris-Saclay, Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche sur les Systèmes Atomiques et Moléculaires Complexes (IRSAMC), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Centre National de la Recherche Scientifique (CNRS), RNSA, Centre National de la Recherche Scientifique (CNRS)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Ear, Nose and Throat, AII - Inflammatory diseases, Pulmonology, CNR, Rome, Italy and Department of Medicine-University of Naples Federico II, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, UCL - SSS/IREC/PNEU - Pôle de Pneumologie, ORL et Dermatologie, UCL - (MGD) Service de pneumologie, Bedard A., Anto J.M., Fonseca J.A., Arnavielhe S., Bachert C., Bedbrook A., Bindslev-Jensen C., Bosnic-Anticevich S., Cardona V., Cruz A.A., Fokkens W.J., Garcia-Aymerich J., Hellings P.W., Ivancevich J.C., Klimek L., Kuna P., Kvedariene V., Larenas-Linnemann D., Melen E., Monti R., Mosges R., Mullol J., Papadopoulos N.G., Pham-Thi N., Samolinski B., Tomazic P.V., Toppila-Salmi S., Ventura M.T., Yorgancioglu A., Bousquet J., Pfaar O., Basagana X., Aberer W., Agache I., Akdis C.A., Akdis M., Aliberti M.R., Almeida R., Amat F., Angles R., Annesi-Maesano I., Ansotegui I.J., Arnavielle S., Asayag E., Asarnoj A., Arshad H., Avolio F., Bacci E., Baiardini I., Barbara C., Barbagallo M., Baroni I., Barreto B.A., Bateman E.D., Bedolla-Barajas M., Bewick M., Beghe B., Bel E.H., Bergmann K.C., Bennoor K.S., Benson M., Bertorello L., Bialoszewski A.Z., Bieber T., Bialek S., Bjermer L., Blain H., Blasi F., Blua A., Bochenska Marciniak M., Bogus-Buczynska I., Boner A.L., Bonini M., Bonini S., Bosse I., Bouchard J., Boulet L.P., Bourret R., Bousquet P.J., Braido F., Briedis V., Brightling C.E., Brozek J., Bucca C., Buhl R., Buonaiuto R., Panaitescu C., Burguete Cabanas M.T., Burte E., Bush A., Caballero-Fonseca F., Caillaud D., Caimmi D., Calderon M.A., Camargos P.A.M., Camuzat T., Canfora G., Canonica G.W., Carlsen K.H., Carreiro-Martins P., Carriazo A.M., Carr W., Cartier C., Casale T., Castellano G., Cecchi L., Cepeda A.M., Chavannes N.H., Chen Y., Chiron R., Chivato T., Chkhartishvili E., Chuchalin A.G., Chung K.F., Ciaravolo M.M., Ciceran A., Cingi C., Ciprandi G., Carvalho Coehlo A.C., Colas L., Colgan E., Coll J., Conforti D., Constantinidis J., Correia de Sousa J., Cortes-Grimaldo R.M., Corti F., Costa E., Costa-Dominguez M.C., Courbis A.L., Cox L., Crescenzo M., Custovic A., Czarlewski W., Dahlen S.E., D'Amato G., Dario C., da Silva J., Dauvilliers Y., Darsow U., De Blay F., De Carlo G., Dedeu T., de Fatima Emerson M., De Feo G., De Vries G., De Martino B., Motta Rubini N.P., Deleanu D., Denburg J.A., Devillier P., Di Capua Ercolano S., Di Carluccio N., Didier A., Dokic D., Dominguez-Silva M.G., Douagui H., Dray G., Dubakiene R., Durham S.R., Du Toit G., Dykewicz M.S., El-Gamal Y., Eklund P., Eller E., Emuzyte R., Farrell J., Farsi A., Ferreira de Mello J., Ferrero J., Fink-Wagner A., Fiocchi A., Fontaine J.F., Forti S., Fuentes-Perez J.M., Galvez-Romero J.L., Gamkrelidze A., Garcia-Cobas C.Y., Garcia-Cruz M.H., Gemicioglu B., Genova S., Christoff G., Gereda J.E., Gerth van Wijk R., Gomez R.M., Gomez-Vera J., Gonzalez Diaz S., Gotua M., Grisle I., Guidacci M., Guldemond N.A., Gutter Z., Guzman M.A., Haahtela T., Hajjam J., Hernandez L., Hourihane J.O.'.B., Huerta-Villalobos Y.R., Humbert M., Iaccarino G., Illario M., Ispayeva Z., Jares E.J., Jassem E., Johnston S.L., Joos G., Jung K.S., Just J., Jutel M., Kaidashev I., Kalayci O., Kalyoncu A.F., Karjalainen J., Kardas P., Keil T., Keith P.K., Khaitov M., Khaltaev N., Kleine-Tebbe J., Kowalski M.L., Kuitunen M., Kull I., Kupczyk M., Krzych-Falta E., Lacwik P., Laune D., Lauri D., Lavrut J., Le L.T.T., Lessa M., Levato G., Li J., Lieberman P., Lipiec A., Lipworth B., Lodrup Carlsen K.C., Louis R., Lourenco O., Luna-Pech J.A., Magnan A., Mahboub B., Maier D., Mair A., Majer I., Malva J., Mandajieva E., Manning P., De Manuel Keenoy E., Marshall G.D., Masjedi M.R., Maspero J.F., Mathieu-Dupas E., Matta Campos J.J., Matos A.L., Maurer M., Mavale-Manuel S., Mayora O., Meco C., Medina-Avalos M.A., Melo-Gomes E., Meltzer E.O., Menditto E., Mercier J., Miculinic N., Mihaltan F., Milenkovic B., Moda G., Mogica-Martinez M.D., Mohammad Y., Momas I., Montefort S., Mora Bogado D., Morais-Almeida M., Morato-Castro F.F., Mota-Pinto A., Moura Santo P., Munter L., Muraro A., Murray R., Naclerio R., Nadif R., Nalin M., Napoli L., Namazova-Baranova L., Neffen H., Niedeberger V., Nekam K., Neou A., Nieto A., Nogueira-Silva L., Nogues M., Novellino E., Nyembue T.D., O'Hehir R.E., Odzhakova C., Ohta K., Okamoto Y., Okubo K., Onorato G.L., Ortega Cisneros M., Ouedraogo S., Pali-Scholl I., Palkonen S., Panzner P., Park H.S., Papi A., Passalacqua G., Paulino E., Pawankar R., Pedersen S., Pepin J.L., Pereira A.M., Persico M., Phillips J., Picard R., Pigearias B., Pin I., Pitsios C., Plavec D., Pohl W., Popov T.A., Portejoie F., Potter P., Pozzi A.C., Price D., Prokopakis E.P., Puy R., Pugin B., Pulido Ross R.E., Przemecka M., Rabe K.F., Raciborski F., Rajabian-Soderlund R., Reitsma S., Ribeirinho I., Rimmer J., Rivero-Yeverino D., Rizzo J.A., Rizzo M.C., Robalo-Cordeiro C., Rodenas F., Rodo X., Rodriguez Gonzalez M., Rodriguez-Manas L., Rolland C., Rodrigues Valle S., Roman Rodriguez M., Romano A., Rodriguez-Zagal E., Rolla G., Roller-Wirnsberger R.E., Romano M., Rosado-Pinto J., Rosario N., Rottem M., Ryan D., Sagara H., Salimaki J., Sanchez-Borges M., Sastre-Dominguez J., Scadding G.K., Schunemann H.J., Scichilone N., Schmid-Grendelmeier P., Sarquis Serpa F., Shamai S., Sheikh A., Sierra M., Simons F.E.R., Siroux V., Sisul J.C., Skrindo I., Sole D., Somekh D., Sondermann M., Sooronbaev T., Sova M., Sorensen M., Sorlini M., Spranger O., Stellato C., Stelmach R., Stukas R., Sunyer J., Strozek J., Szylling A., Tebyrica J.N., Thibaudon M., To T., Todo-Bom A., Trama U., Triggiani M., Suppli Ulrik C., Urrutia-Pereira M., Valenta R., Valero A., Valiulis A., Valovirta E., van Eerd M., van Ganse E., van Hage M., Vandenplas O., Vezzani G., Vasankari T., Vatrella A., Verissimo M.T., Viart F., Viegi G., Vicheva D., Vontetsianos T., Wagenmann M., Walker S., Wallace D., Wang D.Y., Waserman S., Werfel T., Westman M., Wickman M., Williams D.M., Williams S., Wilson N., Wright J., Wroczynski P., Yakovliev P., Yawn B.P., Yiallouros P.K., Yusuf O.M., Zar H.J., Zhang L., Zhong N., Zernotti M.E., Zhanat I., Zidarn M., Zuberbier T., Zubrinich C., and Zurkuhlen A.
- Subjects
0301 basic medicine ,SYMPTOMS ,Smart phone ,Allergy ,Escala visual analógica ,INNOVATION ,[SDV]Life Sciences [q-bio] ,Medical and Health Sciences ,Correlation ,visual analogue scale ,0302 clinical medicine ,Quality of life ,Visual analogue scale ,QUALITY-OF-LIFE ,Màscares ,Immunology and Allergy ,score ,Nose ,Rinitis ,Rhinitis ,PRODUCTIVITY COSTS ,asthma ,MASK ,rhinitis ,Score ,Explained variation ,Response Variability ,Mobile Applications ,ALLERGIC RHINITIS ,rhiniti ,medicine.anatomical_structure ,TRIALS ,Rinite ,1107 Immunology ,[SDV.IMM]Life Sciences [q-bio]/Immunology ,Smartphone ,medicine.medical_specialty ,MASK study group ,Immunology ,MACVIA-ARIA ,03 medical and health sciences ,Allergic ,medicine ,Humans ,TECHNOLOGY ,IMMUNOTHERAPY ,Asma ,Asthma ,business.industry ,Rhinitis, Allergic ,medicine.disease ,RHINOCONJUNCTIVITIS ,030104 developmental biology ,030228 respiratory system ,3121 General medicine, internal medicine and other clinical medicine ,Physical therapy ,Clinical Medicine ,business ,[SDV.MHEP]Life Sciences [q-bio]/Human health and pathology - Abstract
Background: In allergic rhinitis, a relevant outcome providing information on the effectiveness of interventions is needed. In MASK-air (Mobile Airways Sentinel Network), a visual analogue scale (VAS) for work is used as a relevant outcome. This study aimed to assess the performance of the work VAS work by comparing VAS work with other VAS measurements and symptom-medication scores obtained concurrently. Methods: All consecutive MASK-air users in 23 countries from 1 June 2016 to 31 October 2018 were included (14 189 users; 205 904 days). Geolocalized users self-assessed daily symptom control using the touchscreen functionality on their smart phone to click on VAS scores (ranging from 0 to 100) for overall symptoms (global), nose, eyes, asthma and work. Two symptom-medication scores were used: the modified EAACI CSMS score and the MASK control score for rhinitis. To assess data quality, the intra-individual response variability (IRV) index was calculated. Results: A strong correlation was observed between VAS work and other VAS. The highest levels for correlation with VAS work and variance explained in VAS work were found with VAS global, followed by VAS nose, eye and asthma. In comparison with VAS global, the mCSMS and MASK control score showed a lower correlation with VAS work. Results are unlikely to be explained by a low quality of data arising from repeated VAS measures. Conclusions: VAS work correlates with other outcomes (VAS global, nose, eye and asthma) but less well with a symptom-medication score. VAS work should be considered as a potentially useful AR outcome in intervention studies. © 2020 EAACI and John Wiley and Sons A/S. Published by John Wiley and Sons Ltd.
- Published
- 2020
12. DRH1 - Evaluierung eines Blut-basierten Markers für HPV16-induzierte Tumore
- Author
-
Weiland, T, additional, Tomazic, PV, additional, Wolf, A, additional, Brcic, L, additional, Pondorfer-Schäfer, P, additional, Vasicek, S, additional, Holzmeister, C, additional, Kiss, P, additional, Graupp, M, additional, and Thurnher, D, additional
- Published
- 2020
- Full Text
- View/download PDF
13. ARIA Phase 4 (2018): Change management in allergic rhinitis and asthma multimorbidity using mobile technology
- Author
-
Bousquet, J, Hellings, Pw, Agache, I, Amat, F, Annesi-Maesano, I, Ansotegui, Ij, Anto, Jm, Bachert, C, Bateman, Ed, Bedbrook, A, Bennoor, K, Bewick, M, Bindslev-Jensen, C, Bosnic-Anticevich, S, Bosse, I, Brozek, J, Brussino, L, Canonica, Gw, Cardona, V, Casale, T, Cepeda Sarabia AM, Chavannes, Nh, Cecchi, L, Correia de Sousa, J, Costa, E, Cruz, Aa, Czarlewski, W, De Carlo, G, De Feo, G, Demoly, P, Devillier, P, Dykewicz, Ms, El-Gamal, Y, Eller, E, Fonseca, Ja, Fontaine, Jf, Fokkens, Wj, Guzmán, Ma, Haahtela, T, Illario, M, Ivancevich, Jc, Just, J, Kaidashev, I, Khaitov, M, Kalayci, O, Keil, T, Klimek, L, Kowalski, Ml, Kuna, P, Kvedariene, V, Larenas-Linnemann, D, Laune, D, Le, Lt, Carlsen, Kh, Lourenço, O, Mahboub, B, Mair, A, Menditto, E, Milenkovic, B, Morais-Almeida, M, Mösges, R, Mullol, J, Murray, R, Naclerio, R, Namazova-Baranova, L, Novellino, E, O'Hehir, Re, Ohta, K, Okamoto, Y, Okubo, K, Onorato, Gl, Palkonen, S, Panzner, P, Papadopoulos, Ng, Park, Hs, Paulino, E, Pawankar, R, Pfaar, O, Plavec, D, Popov, Ta, Potter, P, Prokopakis, Ep, Rottem, M, Ryan, D, Salimäki, J, Samolinski, B, Sanchez-Borges, M, Schunemann, Hj, Sheikh, A, Sisul, Jc, Rajabian-Söderlund, R, Sooronbaev, T, Stellato, C, To, T, Todo-Bom, Am, Tomazic, Pv, Toppila-Salmi, S, Valero, A, Valiulis, A, Valovirta, E, Ventura, Mt, Wagenmann, M, Wang, Y, Wallace, D, Waserman, S, Wickman, M, Yorgancioglu, A, Zhang, L, Zhong, N, Zidarn, M, Zuberbier, T, Vatrella, Alessandro, and Triggiani, Massimo
- Subjects
ARIA ,rhinitis ,Change management ,asthma - Published
- 2018
14. The Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire Using Mobile Technology: The MASK Study
- Author
-
Bousquet, J, primary, VandenPlas, O, additional, Bewick, M, additional, Arnavielhe, S, additional, Bedbrook, A, additional, Murray, R, additional, van Eerd, M, additional, Fonseca, J, additional, Morais-Almeida, M, additional, Todo Bom, A, additional, Cruz, AA, additional, Sarquis Serpa, F, additional, da Silva, J, additional, Menditto, E, additional, Passalacqua, G, additional, Stellato, C, additional, Ventura, MT, additional, Caimmi, D, additional, Demoly, P, additional, Bergmann, KC, additional, Keil, T, additional, Klimek, L, additional, Mösges, R, additional, Shamai, S, additional, Zuberbier, T, additional, Larenas-Linnemann, D, additional, Rodriguez Gonzalez, M, additional, Burguete Cabañas, MT, additional, Ryan, D, additional, Sheikh, A, additional, Anto, JM, additional, Mullol, J, additional, Valero, A, additional, Kowalski, ML, additional, Kuna, P, additional, Samolinski, B, additional, Tomazic, PV, additional, Bosnic-Anticevich, S, additional, O'Hehir, RE, additional, De Vries, G, additional, and Laune, D, additional
- Published
- 2018
- Full Text
- View/download PDF
15. CHRODIS criteria applied to the MASK (MACVIA-ARIA Sentinel NetworK) Good Practice in allergic rhinitis: a SUNFRAIL report
- Author
-
Bousquet, J, Onorato, GL, Bachert, C, Barbolini, M, Bedbrook, A, Bjermer, L, de Sousa, JC, Chavannes, NH, Cruz, AA, Keenoy, ED, Devillier, P, Fonseca, J, Hun, S, Kostka, T, Hellings, PW, Illario, M, Ivancevich, JC, Larenas-Linnemann, D, Millot-Keurinck, J, Ryan, D, Samolinski, B, Sheikh, A (Aziz), Yorgancioglu, A, Agache, I, Arnavielhe, S, Bewick, M, Annesi-Maesano, I, Anto, JM, Bergmann, KC, Bindslev-Jensen, C, Bosnic-Anticevich, S, Bouchard, J, Caimmi, D P, Camargos, P, Canonica, GW, Cardona, V, Carriazo, AM, Cingi, C, Colgan, E, Custovic, A, Dahl, R, Demoly, P, de Vries, G (Gerard), Fokkens, WJ, Fontaine, JF, Gemicioglu, B, Guldemond, Nick, Gutter, Z, Haahtela, T, Hellqvist-Dahl, B, Jares, E, Joos, G, Just, J, Khaltaev, N, Keil, T, Klimek, L, Kowalski, ML, Kull, I, Kuna, P, Kvedariene, V, Laune, D, Louis, R, Magnan, A, Malva, J, Mathieu-Dupas, E, Melen, E, Menditto, E, Morais-Almeida, M, Mosges, R, Mullol, J, Murray, R, Neffen, H, O'Hehir, R, Palkonen, S, Papadopoulos, NG, Passalacqua, G, Pepin, JL, Portejoie, F, Price, D, Pugin, B, Raciborski, F, Simons, FER, Sova, M, Spranger, O, Stellato, C, Bom, AT, Tomazic, PV, Triggiani, M, Valero, A, Valovirta, E, Vandenplas, O, Valiulis, A, van Eerd, M, Ventura, M T, Wickman, M, Young, I, Zuberbier, T, Zurkuhlen, A, Senn, A, Bousquet, J, Onorato, GL, Bachert, C, Barbolini, M, Bedbrook, A, Bjermer, L, de Sousa, JC, Chavannes, NH, Cruz, AA, Keenoy, ED, Devillier, P, Fonseca, J, Hun, S, Kostka, T, Hellings, PW, Illario, M, Ivancevich, JC, Larenas-Linnemann, D, Millot-Keurinck, J, Ryan, D, Samolinski, B, Sheikh, A (Aziz), Yorgancioglu, A, Agache, I, Arnavielhe, S, Bewick, M, Annesi-Maesano, I, Anto, JM, Bergmann, KC, Bindslev-Jensen, C, Bosnic-Anticevich, S, Bouchard, J, Caimmi, D P, Camargos, P, Canonica, GW, Cardona, V, Carriazo, AM, Cingi, C, Colgan, E, Custovic, A, Dahl, R, Demoly, P, de Vries, G (Gerard), Fokkens, WJ, Fontaine, JF, Gemicioglu, B, Guldemond, Nick, Gutter, Z, Haahtela, T, Hellqvist-Dahl, B, Jares, E, Joos, G, Just, J, Khaltaev, N, Keil, T, Klimek, L, Kowalski, ML, Kull, I, Kuna, P, Kvedariene, V, Laune, D, Louis, R, Magnan, A, Malva, J, Mathieu-Dupas, E, Melen, E, Menditto, E, Morais-Almeida, M, Mosges, R, Mullol, J, Murray, R, Neffen, H, O'Hehir, R, Palkonen, S, Papadopoulos, NG, Passalacqua, G, Pepin, JL, Portejoie, F, Price, D, Pugin, B, Raciborski, F, Simons, FER, Sova, M, Spranger, O, Stellato, C, Bom, AT, Tomazic, PV, Triggiani, M, Valero, A, Valovirta, E, Vandenplas, O, Valiulis, A, van Eerd, M, Ventura, M T, Wickman, M, Young, I, Zuberbier, T, Zurkuhlen, A, and Senn, A
- Published
- 2017
16. ARIA 2016: Care pathways implementing emerging technologies for predictive medicine in rhinitis and asthma across the life cycle
- Author
-
Bousquet, J, Hellings, PW, Agache, I, Bedbrook, A, Bachert, C, Bergmann, KC, Bewick, M, Bindslev-Jensen, C, Bosnic-Anticevitch, S, Bucca, C, Caimmi, D P, Camargos, PAM, Canonica, GW, Casale, T, Chavannes, NH, Cruz, AA, De Carlo, G, Dahl, R, Demoly, P, Devillier, P, Fonseca, J, Fokkens, WJ, Guldemond, Nick, Haahtela, T, Illario, M, Just, J, Keil, T, Klimek, L, Kuna, P, Larenas-Linnemann, D, Morais-Almeida, M, Mullol, J, Murray, R, Naclerio, R, O'Hehir, RE, Papadopoulos, NG, Pawankar, R, Potter, P, Ryan, D, Samolinski, B, Schunemann, HJ, Sheikh, A (Aziz), Simons, FER, Stellato, C, Todo-Bom, A, Tomazic, PV, Valiulis, A, Valovirta, E, Ventura, M T, Wickman, M, Young, I, Yorgancioglu, A, Zuberbier, T, Aberer, W, Akdis, CA, Akdis, M, Annesi-Maesano, I, Ankri, J, Ansotegui, IJ, Anto, JM, Arnavielhe, S, Asarnoj, A, Arshad, H, Avolio, F, Baiardini, I, Barbara, C, Barbagallo, M, Bateman, ED, Beghé, B, Bel, EH, Bennoor, KS, Benson, M, Bia?oszewski, AZ, Bieber, T, Bjermer, L, Blain, H, Blasi, F, Boner, AL, Bonini, M, Bonini, S, Bosse, I, Bouchard, J, Boulet, LP, Bourret, R, Bousquet, PJ, Braido, F, Briggs, AH, Brightling, CE, Brozek, J, Buhl, R, Bunu, C, Burte, E, Bush, A, Caballero-Fonseca, F, Calderon, MA, Camuzat, T, Cardona, V, Carreiro-Martins, P, Carriazo, AM, Carlsen, KH, Carr, W, Cepeda Sarabia, AM, Cesari, M, Chatzi, L, Chiron, R, Chivato, T, Chkhartishvili, E, Chuchalin, AG, Chung, KF, Ciprandi, G, de Sousa, JC, Cox, L, Crooks, G, Custovic, A, Dahlen, SE, Darsow, U, Dedeu, T, Deleanu, D, Denburg, JA, de Vries, G, Didier, A, Dinh-Xuan, AT, Dokic, D, Douagui, H, Dray, G, Dubakiene, R, Durham, SR, Du Toit, G, Dykewicz, MS, Eklund, P, El-Gamal, Y, Ellers, E, Emuzyte, R, Farrell, J, Wagner, A, Fiocchi, A, Fletcher, M, Forastiere, F, Gaga, M, Gamkrelidze, A, Gemicio?lu, B, Gereda, JE, Gerth van Wijk, Roy, González Diaz, S, Grisle, I, Grouse, L, Gutter, Z, Guzmán, MA, Hellquist-Dahl, B, Heinrich, J, Horak, F, Hourihane, JOB, Humbert, M, Hyland, M, Iaccarino, G, Jares, EJ, Jeandel, C, Johnston, SL, Joos, G, Jonquet, O, Jung, KS, Jutel, M, Kaidashev, I, Khaitov, M, Kalayci, O, Kalyoncu, AF, Kardas, P, Keith, PK, Kerkhof, M, Kerstjens, HAM, Khaltaev, N, Kogevinas, M, Kolek, V, Koppelman, GH, Kowalski, ML, Kuitunen, M, Kull, I, Kvedariene, V, Lambrecht, Bart, Lau, S, Laune, D, Le, LTT, Lieberman, P, Lipworth, B, Li, J, Lodrup Carlsen, KC, Louis, R, Lupinek, C, MacNee, W, Magar, Y, Magnan, A, Mahboub, B, Maier, D, Majer, Istvan, Malva, J, Manning, P, De Manuel Keenoy, E, Marshall, GD, Masjedi, MR, Mathieu-Dupas, E, Maurer, M, Mavale-Manuel, S, Melén, E, Melo-Gomes, E, Meltzer, EO, Mercier, J, Merk, H, Miculinic, N, Mihaltan, F, Milenkovic, B, Millot-Keurinck, J, Mohammad, Y, Momas, I, Mösges, R, Muraro, A, Namazova-Baranova, L, Nadif, R, Neffen, H, Nekam, K, Nieto, A, Niggemann, B, Nogueira-Silva, L, Nogues, M, Nyembue, TD, Ohta, K, Okamoto, Y, Okubo, K, Olive-Elias, M, Ouedraogo, S, Paggiaro, P, Pali-Schöll, I, Palkonen, S, Panzner, P, Papi, A, Park, HS, Passalacqua, G, Pedersen, S, Pereira, AM, Pfaar, O, Picard, R, Pigearias, B, Pin, I, Plavec, D, Pohl, W, Popov, TA, Portejoie, F, Postma, D, Poulsen, LK, Price, D, Rabe, KF, Raciborski, F, Roberts, G, Robalo-Cordeiro, C, Rodenas, F, Rodriguez-Mañas, L, Rolland, C, Rodriguez, M, Romano, A, Rosado-Pinto, J, Rosario, N, Rottem, M, Sanchez-Borges, M, Sastre-Dominguez, J, Scadding, GK, Scichilone, N, Schmid-Grendelmeier, P, Serrano, E, Shields, M, Siroux, V, Sisul, JC, Skrindo, I, Smit, HA, Solé, D, Sooronbaev, T, Spranger, O, Stelmach, R, Sterk, PJ, Strandberg, T, Sunyer, J, Thijs, C, Triggiani, M, Valenta, R, Valero, A, van Eerd, M, van Ganse, E, Van Hague, M, Vandenplas, O, Varona, LL, Vellas, B, Vezzani, G, Vazankari, T, Viegi, G, Vontetsianos, T, Wagenmann, M, Walker, S, Wang, DY, Wahn, U, Werfel, T, Whalley, B, Williams, DM, Williams, S, Wilson, N, Wright, J, Yawn, BP, Yiallouros, PK, Yusuf, OM, Zaidi, A, Zar, HJ, Zernotti, ME, Zhang, L, Zhong, N, Zidarn, M, Bousquet, J, Hellings, PW, Agache, I, Bedbrook, A, Bachert, C, Bergmann, KC, Bewick, M, Bindslev-Jensen, C, Bosnic-Anticevitch, S, Bucca, C, Caimmi, D P, Camargos, PAM, Canonica, GW, Casale, T, Chavannes, NH, Cruz, AA, De Carlo, G, Dahl, R, Demoly, P, Devillier, P, Fonseca, J, Fokkens, WJ, Guldemond, Nick, Haahtela, T, Illario, M, Just, J, Keil, T, Klimek, L, Kuna, P, Larenas-Linnemann, D, Morais-Almeida, M, Mullol, J, Murray, R, Naclerio, R, O'Hehir, RE, Papadopoulos, NG, Pawankar, R, Potter, P, Ryan, D, Samolinski, B, Schunemann, HJ, Sheikh, A (Aziz), Simons, FER, Stellato, C, Todo-Bom, A, Tomazic, PV, Valiulis, A, Valovirta, E, Ventura, M T, Wickman, M, Young, I, Yorgancioglu, A, Zuberbier, T, Aberer, W, Akdis, CA, Akdis, M, Annesi-Maesano, I, Ankri, J, Ansotegui, IJ, Anto, JM, Arnavielhe, S, Asarnoj, A, Arshad, H, Avolio, F, Baiardini, I, Barbara, C, Barbagallo, M, Bateman, ED, Beghé, B, Bel, EH, Bennoor, KS, Benson, M, Bia?oszewski, AZ, Bieber, T, Bjermer, L, Blain, H, Blasi, F, Boner, AL, Bonini, M, Bonini, S, Bosse, I, Bouchard, J, Boulet, LP, Bourret, R, Bousquet, PJ, Braido, F, Briggs, AH, Brightling, CE, Brozek, J, Buhl, R, Bunu, C, Burte, E, Bush, A, Caballero-Fonseca, F, Calderon, MA, Camuzat, T, Cardona, V, Carreiro-Martins, P, Carriazo, AM, Carlsen, KH, Carr, W, Cepeda Sarabia, AM, Cesari, M, Chatzi, L, Chiron, R, Chivato, T, Chkhartishvili, E, Chuchalin, AG, Chung, KF, Ciprandi, G, de Sousa, JC, Cox, L, Crooks, G, Custovic, A, Dahlen, SE, Darsow, U, Dedeu, T, Deleanu, D, Denburg, JA, de Vries, G, Didier, A, Dinh-Xuan, AT, Dokic, D, Douagui, H, Dray, G, Dubakiene, R, Durham, SR, Du Toit, G, Dykewicz, MS, Eklund, P, El-Gamal, Y, Ellers, E, Emuzyte, R, Farrell, J, Wagner, A, Fiocchi, A, Fletcher, M, Forastiere, F, Gaga, M, Gamkrelidze, A, Gemicio?lu, B, Gereda, JE, Gerth van Wijk, Roy, González Diaz, S, Grisle, I, Grouse, L, Gutter, Z, Guzmán, MA, Hellquist-Dahl, B, Heinrich, J, Horak, F, Hourihane, JOB, Humbert, M, Hyland, M, Iaccarino, G, Jares, EJ, Jeandel, C, Johnston, SL, Joos, G, Jonquet, O, Jung, KS, Jutel, M, Kaidashev, I, Khaitov, M, Kalayci, O, Kalyoncu, AF, Kardas, P, Keith, PK, Kerkhof, M, Kerstjens, HAM, Khaltaev, N, Kogevinas, M, Kolek, V, Koppelman, GH, Kowalski, ML, Kuitunen, M, Kull, I, Kvedariene, V, Lambrecht, Bart, Lau, S, Laune, D, Le, LTT, Lieberman, P, Lipworth, B, Li, J, Lodrup Carlsen, KC, Louis, R, Lupinek, C, MacNee, W, Magar, Y, Magnan, A, Mahboub, B, Maier, D, Majer, Istvan, Malva, J, Manning, P, De Manuel Keenoy, E, Marshall, GD, Masjedi, MR, Mathieu-Dupas, E, Maurer, M, Mavale-Manuel, S, Melén, E, Melo-Gomes, E, Meltzer, EO, Mercier, J, Merk, H, Miculinic, N, Mihaltan, F, Milenkovic, B, Millot-Keurinck, J, Mohammad, Y, Momas, I, Mösges, R, Muraro, A, Namazova-Baranova, L, Nadif, R, Neffen, H, Nekam, K, Nieto, A, Niggemann, B, Nogueira-Silva, L, Nogues, M, Nyembue, TD, Ohta, K, Okamoto, Y, Okubo, K, Olive-Elias, M, Ouedraogo, S, Paggiaro, P, Pali-Schöll, I, Palkonen, S, Panzner, P, Papi, A, Park, HS, Passalacqua, G, Pedersen, S, Pereira, AM, Pfaar, O, Picard, R, Pigearias, B, Pin, I, Plavec, D, Pohl, W, Popov, TA, Portejoie, F, Postma, D, Poulsen, LK, Price, D, Rabe, KF, Raciborski, F, Roberts, G, Robalo-Cordeiro, C, Rodenas, F, Rodriguez-Mañas, L, Rolland, C, Rodriguez, M, Romano, A, Rosado-Pinto, J, Rosario, N, Rottem, M, Sanchez-Borges, M, Sastre-Dominguez, J, Scadding, GK, Scichilone, N, Schmid-Grendelmeier, P, Serrano, E, Shields, M, Siroux, V, Sisul, JC, Skrindo, I, Smit, HA, Solé, D, Sooronbaev, T, Spranger, O, Stelmach, R, Sterk, PJ, Strandberg, T, Sunyer, J, Thijs, C, Triggiani, M, Valenta, R, Valero, A, van Eerd, M, van Ganse, E, Van Hague, M, Vandenplas, O, Varona, LL, Vellas, B, Vezzani, G, Vazankari, T, Viegi, G, Vontetsianos, T, Wagenmann, M, Walker, S, Wang, DY, Wahn, U, Werfel, T, Whalley, B, Williams, DM, Williams, S, Wilson, N, Wright, J, Yawn, BP, Yiallouros, PK, Yusuf, OM, Zaidi, A, Zar, HJ, Zernotti, ME, Zhang, L, Zhong, N, and Zidarn, M
- Published
- 2016
17. Beurteilung von Nasennebenhöhlen-CT Scans bei Transplantatempfängern
- Author
-
Lang-Loidolt, D, Neuschitzer, A, and Tomazic, PV
- Subjects
ddc: 610 ,610 Medical sciences ,Medicine - Abstract
Hintergrund: Organtransplantationen sind immer mit einer lebenslangen Immunsuppression verbunden. Vor der Transplantation wird daher zum Ausschluss potentieller Infektionsherde unter Anderem ein Nasennebenhöhlen-CT veranlasst. Bei einem pathologischen CT Befund wird zumeist eine FESS durchgeführt,[for full text, please go to the a.m. URL], 81. Jahresversammlung der Deutschen Gesellschaft für Hals-Nasen-Ohren-Heilkunde, Kopf- und Hals-Chirurgie
- Published
- 2010
- Full Text
- View/download PDF
18. Misdiagnosis of acute peripheral vestibulopathy in central nervous ischemic infarction.
- Author
-
Braun EM, Tomazic PV, Ropposch T, Nemetz U, Lackner A, and Walch C
- Published
- 2011
- Full Text
- View/download PDF
19. Management of otogenic sigmoid sinus thrombosis.
- Author
-
Ropposch T, Nemetz U, Braun EM, Lackner A, Tomazic PV, and Walch C
- Published
- 2011
- Full Text
- View/download PDF
20. Giant middle ear squamous cell carcinoma mimicking as cholesteatoma.
- Author
-
Tomazic PV, Ropposch T, Karpf EF, Nemetz U, Braun EM, Lackner A, and Walch C
- Published
- 2012
- Full Text
- View/download PDF
21. Medullary infarction after vertebral artery dissection presenting as acute peripheral vertigo.
- Author
-
Braun EM, Tomazic PV, Ropposch T, Satran A, and Walch C
- Published
- 2011
- Full Text
- View/download PDF
22. Benefits and harm of systemic steroids for short- and long-term use in rhinitis and rhinosinusitis: an EAACI position paper
- Author
-
Hox, Valerie, Lourijsen, Evelijn, Jordens, Arnout, Aasbjerg, Kristian, Agache, Ioana, Alobid, Isam, Bachert, Claus, Boussery, Koen, Campo, Paloma, Fokkens, Wytske, Hellings, Peter, Hopkins, Claire, Klimek, Ludger, Makelä, Mika, Moesges, Ralph, Mullol, Joaquim, Pujols, Laura, Rondon, Carmen, Rudenko, Michael, Toppila-Salmi, Sanna, Scadding, Glenis, Scheire, Sophie, Tomazic, Peter-Valentin, Van Zele, Thibaut, Wagemann, Martin, van Boven, Job F. M., Gevaert, Philippe, [Hox,V] Cliniques Universitaires Saint-Luc Brussels, Brussels, Belgium. [Lourijsen,E, Fokkens,W] Department of Otorhinolaryngology, Amsterdam University Medical Centres, AMC, Amsterdam, The Netherlands. [Jordens,A, Bachert,C, Van Zele,T, Gevaert,P] Upper Airway Research Laboratory, Dep. of Otorhinolaryngology, Ghent University Hospital, Ghent, Belgium. [Aasbjerg,K] Bispebjerg University Hospital, Copenhagen, Denmark. [Agache,I] Faculty of Medicine, Transsylvania University, Brasov, Romania. [Alobid,I, Mullol,J, Pujols,L] Hospital Clínic, IDIBAPS, CEBERES Universitat de Barcelona, Catalonia, Spain. [Alobid,I] Centro Medico Teknon, Barcelona, Spain. [Bachert,C] Department of Ear, Nose and Throat Diseases, Karolinska University Hospital, Stockholm, Sweden. [Boussery,K, Scheire,S] Pharmaceutical Care Unit, Faculty of Pharmaceutical Sciences, Ghent University, Ghent, Belgium. [Campo,P, Rondon,C] Allergy Unit, Hospital Regional Universitario of Málaga, IBIMA, ARADyAL, Malaga, Spain. [Hellings,P] Department of Ear, Nose and Throat Disease, University Hospitals, Louvain, Belgium. [Hopkins,C] ENT Department, Guy’s & St Thomas’ Hospital, London, UK. [Klimek,L] Center of Rhinology and Allergology, Wiesbaden, Germany. [Mäkelä,M, Toppila‑Salmi,S] Skin and Allergy Hospital, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. [Mösges,R] University of Cologne, Cologne, Germany. [Rudenko,M] London Allergy and Immunology Center, London, UK. [Scadding,G] Royal National Throat, Nose and Ear Hospital, London, UK. [Tomazic,PV] Medical University Graz, Graz, Austria. [Wagemann,M] Heinrich-Heine-University, Düsseldorf, Germany. [van Boven,JFM] Department of Clinical Pharmacy & Pharmacology, University Medical Center Groningen, Groningen Research Institute for Asthma and COPD (GRIAC), University of Groningen, Groningen, The Netherlands., This work was funded by an EAACI Task Force budget., HUS Inflammation Center, Department of Dermatology, Allergology and Venereology, and University of Helsinki
- Subjects
SEASONAL ALLERGIC RHINITIS ,Rhinosinusitis ,Diseases::Otorhinolaryngologic Diseases::Nose Diseases::Rhinitis [Medical Subject Headings] ,Diseases::Otorhinolaryngologic Diseases::Nose Diseases::Nasal Polyps [Medical Subject Headings] ,Pólipos nasales ,Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings] ,DOUBLE-BLIND ,WEGENERS-GRANULOMATOSIS ,ORAL STEROIDS ,SEVERE NASAL POLYPOSIS ,Sinusitis ,Glucocorticoides ,Rinitis ,Corticoesteroides ,Rhinitis ,CORTICOSTEROID-THERAPY ,Diseases::Otorhinolaryngologic Diseases::Nose Diseases::Paranasal Sinus Diseases::Sinusitis [Medical Subject Headings] ,Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones [Medical Subject Headings] ,Glucocorticosteroids ,RHEUMATOID-ARTHRITIS ,Chemicals and Drugs::Hormones, Hormone Substitutes, and Hormone Antagonists::Hormones::Adrenal Cortex Hormones::Glucocorticoids [Medical Subject Headings] ,3121 General medicine, internal medicine and other clinical medicine ,GLUCOCORTICOID-RECEPTOR-ALPHA ,BONE-MINERAL DENSITY ,ENDOSCOPIC SINUS SURGERY - Abstract
Correction: Volume: 10 Issue: 1 Article Number: 38 DOI: 10.1186/s13601-020-00343-w Published: SEP 28 2020 Because of the inflammatory mechanisms of most chronic upper airway diseases such as rhinitis and chronic rhinosinusitis, systemic steroids have been used for their treatment for decades. However, it has been very well documented that-potentially severe-side-effects can occur with the accumulation of systemic steroid courses over the years. A consensus document summarizing the benefits of systemic steroids for each upper airway disease type, as well as highlighting the potential harms of this treatment is currently lacking. Therefore, a panel of international experts in the field of Rhinology reviewed the available literature with the aim of providing recommendations for the use of systemic steroids in treating upper airway disease.
- Published
- 2020
23. Video endoscopic oro-nasal visualisation of the anterior wall of maxillary sinus: a new technique
- Author
-
Matteo Trimarchi, Pv, Tomazic, Bertazzoni G, Rathburn A, Bussi M, Stammberger H, Trimarchi, Matteo, Tomazic, Pv, Bertazzoni, G, Rathburn, A, Bussi, Mario, and Stammberger, H.
- Subjects
Mouth ,Cadaver dissection ,Oro-nasal endoscopic approach (ONEA) ,otorhinolaryngologic diseases ,Cadaver ,Video Recording ,Humans ,Endoscopy ,Rhinology ,Maxillary Sinus ,Nose ,Endoscopic surgery - Abstract
The anterior wall of the maxillary sinus represents a blind spot in maxillary sinus endoscopic surgery because of the absence of proper visualisation and instrumentation to reach it. The aim of this study was to validate a new approach through the oral cavity into the nose with a flexible video endoscope (oro-nasal endoscopic approach; ONEA) to visualise the entire anterior maxillary wall including the anteromedial angle. We started from a dried bone cadaver model, and then dissected fresh-frozen cadavers. The maxillary sinus was explored with a rigid and a flexible endoscope entering from the nose. Next, a flexible endoscope was introduced through the mouth and back up through the choana, it accessed the maxillary middle antrostomy, entering inside the sinus and looking at the anterior wall. A small ruler inserted inside the sinus demonstrated all the angles visualised. The new ONEA technique allows complete visualisation of the anterior wall of the maxillary sinus with inspection of all blind spots. It is therefore possible to detect lesions that would normally not be visible with a normal rigid endoscope. We demonstrate the validity of a novel technique that allows visualisation of the infero-medial angle of the anterior wall of the maxillary sinus.La parete anteriore del seno mascellare rappresenta un punto cieco nella chirurgia endoscopica del seno mascellare a causa dell'impossibilità di visualizzarla correttamente e della strumentazione adatta a raggiungerla. L'obiettivo del presente studio è stato di convalidare un nuovo approccio attraverso il cavo orale fino nel naso con un video-endoscopio flessibile (approccio oro-nasale endoscopico - ONEA) per visualizzare la parete anteriore del mascellare nella sua interezza, includendo l'angolo antero-mediale. Abbiamo iniziato la nostra indagine su un modello scheletrico e poi su cadavere. Il seno mascellare è stato esplorato con endoscopi rigidi e flessibili entrando dal naso. Poi un endoscopio flessibile è stato introdotto dal cavo orale e attraverso la coana, accendendo alla antrostomia media del mascellare, entrando nel seno ed esaminando la parete anteriore. Un piccolo righello inserito nel seno ha mostrato tutti gli angoli visualizzati. La nuova tecnica ONEA permette la completa visualizzazione della parete anteriore del seno mascellare ispezionando tutti i punti ciechi. È possibile pertanto visualizzare lesioni che non sarebbero altrimenti visibili con un endoscopio rigido normale. Abbiamo quindi dimostrato la validità di una nuova tecnica che permette la visualizzazione dell'angolo infero-mediale della parete anteriore del seno mascellare.
- Published
- 2014
24. Endoscopic transnasal intraorbital surgery: our experience with 16 cases
- Author
-
Paolo, Castelnuovo, Iacopo, Dallan, Davide, Locatelli, Paolo, Battaglia, Paolo, Farneti, Peter Valentin, Tomazic, Veronica, Seccia, Apostolos, Karligkiotis, Apostolous, Karligktios, Ernesto, Pasquini, Heinz, Stammberger, Castelnuovo P, Dallan I, Locatelli D, Battaglia P, Farneti P, Tomazic PV, Seccia V, Karligkiotis A, Pasquini E, and Stammberger H
- Subjects
Male ,Natural Orifice Endoscopic Surgery ,medicine.medical_specialty ,Optic nerve ,Medial compartment ,Endoscopic surgery ,Intraorbital space ,Ophthalmic artery ,Orbital anatomy ,Humans ,Medicine ,Abscess ,Retrospective Studies ,Diplopia ,medicine.diagnostic_test ,business.industry ,Enophthalmos ,Medial rectus muscle ,Endoscopy ,General Medicine ,medicine.disease ,Surgery ,Treatment Outcome ,Otorhinolaryngology ,Orbital Neoplasms ,Female ,Neurosurgery ,medicine.symptom ,business - Abstract
The objective of the study is to present our multicentric experience on intraorbital lesions managed by means of an endonasal endoscopic approach. The study design used was multi-institutional retrospective review. We collected data on 16 intraorbital medially-located lesions, all managed by means of an endonasal route, treated in four different skull base centers. We retrospectively reviewed the technical details, complications, histology, and general outcome. The endoscopic endonasal approach was effective in removing completely intraorbital extra-intraconal tumors in 8 cases, in performing biopsies for histological diagnosis in 6 intraorbital intraconal tumors, and in draining 1 extraconal abscess. No major complications were observed; in particular, there was no optic nerve damage. Minor, temporary complications (diplopia) were seen in 3 cases; only 2 patients experienced a permanent diplopia related to medial rectus muscle impairment, in 1 case associated with enophthalmos. Our preliminary multi-centric clinical experience suggests that medially located intraorbital lesions, and in particular the infero-medial ones, can be successfully and safely managed by such an approach. The well-known advantages of the endoscopic techniques, namely the lack of external scars, less bleeding, shorter hospital stay, and fewer complications, are confirmed.
- Published
- 2012
25. Real-world effectiveness of dupilumab in a European cohort of CRSwNP (CHRINOSOR).
- Author
-
Seys SF, Schneider S, de Kinderen J, Reitsma S, Cavaliere C, Tomazic PV, Morgenstern C, Mortuaire G, Wagenmann M, Bettio G, Ciofalo A, Diamant Z, Eckl-Dorna J, Fokkens WJ, Holzmeister C, Mariën G, Masieri S, Otten J, Scheckenbach K, Tu A, and Bachert C
- Abstract
Background: Pivotal studies with dupilumab demonstrated clinically relevant improvements in nasal polyp score (NPS), symptom and quality of life scores in patients with chronic rhinosinusitis with nasal polyps (CRSwNP)., Objective: We evaluated the effectiveness of dupilumab in a large-scale CRSwNP cohort from 6 European tertiary care centres., Methodology: NPS, SinoNasal Outcome Test (SNOT)-22 score, visual analogue scale (VAS) for total sinus symptoms, loss of smell (LoS) and nasal blockage (NB), and Asthma Control Test (ACT) score were collected from hospital records and assessed at baseline, 24 and 52 weeks of treatment of dupilumab in CRSwNP patients. Treatment effectiveness was evaluated in relation to demographic and lifestyle factors, sinus surgery history, presence of comorbidities and blood eosinophil counts (BEC). Treatment response was evaluated according to EUFOREA 2021 criteria., Results: All patient outcomes improved at 24 and 52 weeks of treatment compared to baseline. Dupilumab showed effectiveness independent of age, sex, body mass index, smoking status, prior sinus surgery, presence of asthma, NSAID exacerbated respiratory disease (NERD), allergy or baseline BEC. 92.5% and 94.4% showed an improvement in at least 1 EUFOREA criterion at 24 and 52 weeks respectively. 54.4% and 68.2% reached all 4 of the more stringent EUFOREA criteria at 24 and 52 weeks respectively., Conclusions: Real-world evaluation of dupilumab effectiveness demonstrates a robust and sustained response in at least two thirds of patients at 52 weeks of treatment. Favourable treatment response was independent of the number of sinus surgery procedures, major comorbidities or baseline systemic levels of type 2 inflammation., (Copyright © 2024. Published by Elsevier Inc.)
- Published
- 2024
- Full Text
- View/download PDF
26. Impact of Overweight on Response to Dupilumab Treatment in Chronic Rhinosinusitis with Nasal Polyps.
- Author
-
Habenbacher M, Moser U, Abaira A, Tomazic PV, Kiss P, Holzmeister C, Pock J, Walla K, Lang A, and Andrianakis A
- Subjects
- Humans, Male, Female, Retrospective Studies, Middle Aged, Chronic Disease, Adult, Treatment Outcome, Obesity complications, Obesity drug therapy, Aged, Quality of Life, Rhinosinusitis, Nasal Polyps drug therapy, Nasal Polyps complications, Sinusitis drug therapy, Sinusitis complications, Antibodies, Monoclonal, Humanized therapeutic use, Rhinitis drug therapy, Rhinitis complications, Overweight complications, Overweight drug therapy, Body Mass Index
- Abstract
Chronic rhinosinusitis with nasal polyps (CRSwNP) significantly impacts quality of life and often presents therapeutic challenges, with biologics like dupilumab showing promise in managing severe, uncontrolled cases. The aim of this study was to assess the influence of overweight on the effectiveness of dupilumab in patients with uncontrolled CRSwNP. This retrospective study analyzed treatment outcomes of 75 CRSwNP patients receiving dupilumab, categorizing them into underweight/normal-weight (BMI ≤ 24.9 kg/m
2 ) and overweight/obese (BMI ≥ 25 kg/m2 ) groups. Outcome measures included changes in nasal polyp score (NPS) and sinonasal outcome test (SNOT-22) scores. Results demonstrated that the underweight/normal-weight group experienced significantly greater improvements in NPS and a higher rate of total NPS improvement compared to the overweight/obese group. While SNOT-22 scores improved in both groups, no significant differences were observed. Among patients with comorbid asthma, the underweight/normal-weight subgroup also showed significantly better outcomes, including greater reductions in both NPS and SNOT-22 scores. Multiple regression analysis identified BMI as an independent prognostic factor for NPS outcomes. The findings suggest that overweight/obesity adversely affects the response to dupilumab in CRSwNP, emphasizing the need for personalized treatment strategies considering BMI.- Published
- 2024
- Full Text
- View/download PDF
27. The value of beta trace protein in CSF-leakage detection confirmed by endoscopic fluorescein evaluation.
- Author
-
Habenbacher M, Sebastnik D, Moser U, Andrianakis A, Kiss P, Alsukayt M, Pock J, Walla K, Maitz E, and Tomazic PV
- Abstract
Cerebrospinal fluid (CSF) leaks originating from defects within the anterior and middle cranial fossa typically manifest as unilateral clear watery rhinorrhea. Continuous CSF leakage mandates surgical repair due to the risk of meningitis and brain abscess. It can be categorized based on its underlying etiology into traumatic, iatrogenic and non-traumatic CSF leaks.
- Published
- 2024
- Full Text
- View/download PDF
28. "A star is born"-A unique case of an intranasal foreign body.
- Author
-
Andrianakis A and Tomazic PV
- Subjects
- Humans, Foreign Bodies diagnostic imaging, Foreign Bodies surgery
- Published
- 2024
- Full Text
- View/download PDF
29. EUFOREA/EPOS2020 statement on the clinical considerations for chronic rhinosinusitis with nasal polyps care.
- Author
-
Hellings PW, Alobid I, Anselmo-Lima WT, Bernal-Sprekelsen M, Bjermer L, Caulley L, Chaker A, Constantinidis J, Conti DM, De Corso E, Desrosiers M, Diamant Z, Gevaert P, Han JK, Heffler E, Hopkins C, Landis BN, Lourenco O, Lund V, Luong AU, Mullol J, Peters A, Philpott C, Reitsma S, Ryan D, Scadding G, Senior B, Tomazic PV, Toskala E, Van Zele T, Viskens AS, Wagenmann M, and Fokkens WJ
- Subjects
- Humans, Chronic Disease, Disease Management, Nasal Polyps therapy, Nasal Polyps diagnosis, Rhinosinusitis diagnosis, Rhinosinusitis therapy
- Abstract
Following the European Forum for Research and Education in Allergy and Airway Diseases (EUFOREA) treatment algorithm for chronic rhinosinusitis (CRS) with nasal polyps (CRSwNP), patients suffering from severe uncontrolled CRSwNP are recommended to receive oral corticosteroids, (revision) sinus surgery, systemic biologicals and/or aspirin treatment after desensitization (ATAD). Given the major differences in indications, outcomes, practical considerations, risks and costs of these key pillars of treatment, there is a growing need to define criteria for each treatment option and list the clinically relevant and major considerations for them. This EUFOREA document therefore provides an expert panel overview of the expected outcomes, specific considerations and (contra)indications of the five major treatment arms of severe uncontrolled CRSwNP: oral corticosteroids, primary and revision sinus surgery, biological treatment and ATAD. This overview of treatment considerations is needed to allow physicians and patients to consider the different options in the context of providing optimal and personalized care for severe uncontrolled CRSwNP. In conclusion, the five major treatment options for severe uncontrolled CRSwNP have intrinsic advantages, specific indications and considerations that are of importance to the patient, the physician and the society. This EUFOREA statement supports the unmet need to define criteria for the indication of every treatment pillar of CRSwNP., (© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
30. Endoscopic trans-sphenoidal pituitary surgery does not impact postoperative nasal quality of life.
- Author
-
Weiland T, Gellner V, Pondorfer P, Hortobagyi D, Maitz E, Kiss P, Borenich A, Reininghaus EZ, Thurnher D, and Tomazic PV
- Subjects
- Humans, Quality of Life, Prospective Studies, Longitudinal Studies, Treatment Outcome, Endoscopy, Pituitary Gland surgery, Turbinates surgery, Pituitary Neoplasms surgery, Pituitary Diseases
- Abstract
Purpose: The aim of this prospective longitudinal study was to assess both subjective quality of life using questionnaires and objective examination of nasal function with regard to olfaction, nasal air flow and mucociliary clearance in patients after minimally invasive, turbinate-preserving endoscopic transnasal trans-sphenoidal pituitary surgery., Methods: Patients undergoing endoscopic transnasal pituitary surgery were recruited prospectively and examined during three study visits, preoperatively and 3 and 6 months postoperatively. We examined nasal function using sniffin' sticks test, rhinomanometry, saccharin transit time test, and endoscopic and radiological scores. In addition, the influence on subjective quality of life and mental health was recorded using the Sinonasal-Outcome-Test-20 (SNOT-20) and the Hospital-Anxiety-and-Depression-Scale (HADS)., Results: 20 patients undergoing endoscopic pituitary tumor resections were included. No significant changes in olfaction or mucociliary clearance were noted. Nasal air flow showed a tendency to increase in the postoperative course lacking significance. Both the endoscopy and the radiological scores showed a significant deterioration, especially after 3 months, with a trend towards improvement over time. However, neither the SNOT-20 nor the HADS showed significant changes compared to baseline., Conclusions: Our concept of minimally invasive endoscopic tumor resections on the pituitary gland with preservation of nasal turbinates shows low morbidity for the patient. Despite objectifiable surgery-associated changes in the nose, nasal physiology in terms of smell, airflow and mucociliary clearance can be preserved and the subjective quality of life of our patients remains stable., (© 2023. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF
31. Consensus criteria for chronic rhinosinusitis disease control: an international Delphi Study.
- Author
-
Sedaghat AR, Fokkens WJ, Lund VJ, Hellings PW, Kern RC, Reitsma S, Toppila-Salmi S, Bernal-Sprekelsen M, Mullol J, Gevaert P, Teeling T, Alobid I, Anselmo-Lima WT, Baroody FM, Cervin A, Cohen NA, Constantinidis J, De Gabory L, Desrosiers M, Harvey RJ, Kalogjera L, Knill A, Landis BN, Meco C, Philpott CM, Ryan D, Schlosser RJ, Senior BA, Smith TL, Tomazic PV, Zhang L, and Hopkins C
- Subjects
- Humans, Consensus, Quality of Life, Delphi Technique, Adrenal Cortex Hormones, Chronic Disease, Nasal Obstruction, Rhinitis diagnosis, Sinusitis diagnosis, Sinusitis therapy, Nasal Polyps diagnosis
- Abstract
Background: Chronic rhinosinusitis (CRS) disease control is a global metric of disease status for CRS. While there is broad acceptance that it is an important treatment goal, there has been inconsistency in the criteria used to define CRS control. The objective of this study was to identify and develop consensus around essential criteria for assessment of CRS disease control., Methods: Modified Delphi methodology consisting of three rounds to review a list of 24 possible CRS control criteria developed by a 12-person steering committee. The core authorship of the multidisciplinary EPOS 2020 guidelines was invited to participate., Results: Thirty-two individuals accepted the invitation to participate and there was no dropout of participants throughout the entire study (3 rounds). Consensus essential criteria for assessment of CRS control were: overall symptom severity, need for CRS-related systemic corticosteroids in the prior 6 months, severity of nasal obstruction, and patient-reported CRS control. Near-consensus items were: nasal endoscopy findings, severity of smell loss, overall quality of life, impairment of normal activities and severity of nasal discharge. Participants’ comments provided insights into caveats of, and disagreements related to, near-consensus items., Conclusions: Overall symptom severity, use of CRS-related systemic corticosteroids, severity of nasal obstruction, and patient-reported CRS control are widely agreed upon essential criteria for assessment of CRS disease control. Consideration of near-consensus items to assess CRS control should be implemented with their intrinsic caveats in mind. These identified consensus CRS control criteria, together with evidence-based support, will provide a foundation upon which CRS control criteria with wide-spread acceptance can be developed.
- Published
- 2023
- Full Text
- View/download PDF
32. Rhinitis associated with asthma is distinct from rhinitis alone: The ARIA-MeDALL hypothesis.
- Author
-
Bousquet J, Melén E, Haahtela T, Koppelman GH, Togias A, Valenta R, Akdis CA, Czarlewski W, Rothenberg M, Valiulis A, Wickman M, Akdis M, Aguilar D, Bedbrook A, Bindslev-Jensen C, Bosnic-Anticevich S, Boulet LP, Brightling CE, Brussino L, Burte E, Bustamante M, Canonica GW, Cecchi L, Celedon JC, Chaves Loureiro C, Costa E, Cruz AA, Erhola M, Gemicioglu B, Fokkens WJ, Garcia-Aymerich J, Guerra S, Heinrich J, Ivancevich JC, Keil T, Klimek L, Kuna P, Kupczyk M, Kvedariene V, Larenas-Linnemann DE, Lemonnier N, Lodrup Carlsen KC, Louis R, Makela M, Makris M, Maurer M, Momas I, Morais-Almeida M, Mullol J, Naclerio RN, Nadeau K, Nadif R, Niedoszytko M, Okamoto Y, Ollert M, Papadopoulos NG, Passalacqua G, Patella V, Pawankar R, Pham-Thi N, Pfaar O, Regateiro FS, Ring J, Rouadi PW, Samolinski B, Sastre J, Savouré M, Scichilone N, Shamji MH, Sheikh A, Siroux V, Sousa-Pinto B, Standl M, Sunyer J, Taborda-Barata L, Toppila-Salmi S, Torres MJ, Tsiligianni I, Valovirta E, Vandenplas O, Ventura MT, Weiss S, Yorgancioglu A, Zhang L, Abdul Latiff AH, Aberer W, Agache I, Al-Ahmad M, Alobid I, Ansotegui IJ, Arshad SH, Asayag E, Barbara C, Baharudin A, Battur L, Bennoor KS, Berghea EC, Bergmann KC, Bernstein D, Bewick M, Blain H, Bonini M, Braido F, Buhl R, Bumbacea RS, Bush A, Calderon M, Calvo-Gil M, Camargos P, Caraballo L, Cardona V, Carr W, Carreiro-Martins P, Casale T, Cepeda Sarabia AM, Chandrasekharan R, Charpin D, Chen YZ, Cherrez-Ojeda I, Chivato T, Chkhartishvili E, Christoff G, Chu DK, Cingi C, Correia de Sousa J, Corrigan C, Custovic A, D'Amato G, Del Giacco S, De Blay F, Devillier P, Didier A, do Ceu Teixeira M, Dokic D, Douagui H, Doulaptsi M, Durham S, Dykewicz M, Eiwegger T, El-Sayed ZA, Emuzyte R, Fiocchi A, Fyhrquist N, Gomez RM, Gotua M, Guzman MA, Hagemann J, Hamamah S, Halken S, Halpin DMG, Hofmann M, Hossny E, Hrubiško M, Irani C, Ispayeva Z, Jares E, Jartti T, Jassem E, Julge K, Just J, Jutel M, Kaidashev I, Kalayci O, Kalyoncu AF, Kardas P, Kirenga B, Kraxner H, Kull I, Kulus M, La Grutta S, Lau S, Le Tuyet Thi L, Levin M, Lipworth B, Lourenço O, Mahboub B, Martinez-Infante E, Matricardi P, Miculinic N, Migueres N, Mihaltan F, Mohammad Y, Moniuszko M, Montefort S, Neffen H, Nekam K, Nunes E, Nyembue Tshipukane D, O'Hehir R, Ogulur I, Ohta K, Okubo K, Ouedraogo S, Olze H, Pali-Schöll I, Palomares O, Palosuo K, Panaitescu C, Panzner P, Park HS, Pitsios C, Plavec D, Popov TA, Puggioni F, Quirce S, Recto M, Repka-Ramirez MS, Robalo Cordeiro C, Roche N, Rodriguez-Gonzalez M, Romantowski J, Rosario Filho N, Rottem M, Sagara H, Serpa FS, Sayah Z, Scheire S, Schmid-Grendelmeier P, Sisul JC, Sole D, Soto-Martinez M, Sova M, Sperl A, Spranger O, Stelmach R, Suppli Ulrik C, Thomas M, To T, Todo-Bom A, Tomazic PV, Urrutia-Pereira M, Valentin-Rostan M, Van Ganse E, van Hage M, Vasankari T, Vichyanond P, Viegi G, Wallace D, Wang DY, Williams S, Worm M, Yiallouros P, Yusuf O, Zaitoun F, Zernotti M, Zidarn M, Zuberbier J, Fonseca JA, Zuberbier T, and Anto JM
- Subjects
- Humans, Allergens, Multimorbidity, Rhinitis diagnosis, Rhinitis epidemiology, Rhinitis complications, Asthma diagnosis, Asthma epidemiology, Asthma etiology, Rhinitis, Allergic complications
- Abstract
Asthma, rhinitis, and atopic dermatitis (AD) are interrelated clinical phenotypes that partly overlap in the human interactome. The concept of "one-airway-one-disease," coined over 20 years ago, is a simplistic approach of the links between upper- and lower-airway allergic diseases. With new data, it is time to reassess the concept. This article reviews (i) the clinical observations that led to Allergic Rhinitis and its Impact on Asthma (ARIA), (ii) new insights into polysensitization and multimorbidity, (iii) advances in mHealth for novel phenotype definitions, (iv) confirmation in canonical epidemiologic studies, (v) genomic findings, (vi) treatment approaches, and (vii) novel concepts on the onset of rhinitis and multimorbidity. One recent concept, bringing together upper- and lower-airway allergic diseases with skin, gut, and neuropsychiatric multimorbidities, is the "Epithelial Barrier Hypothesis." This review determined that the "one-airway-one-disease" concept does not always hold true and that several phenotypes of disease can be defined. These phenotypes include an extreme "allergic" (asthma) phenotype combining asthma, rhinitis, and conjunctivitis. Rhinitis alone and rhinitis and asthma multimorbidity represent two distinct diseases with the following differences: (i) genomic and transcriptomic background (Toll-Like Receptors and IL-17 for rhinitis alone as a local disease; IL-33 and IL-5 for allergic and non-allergic multimorbidity as a systemic disease), (ii) allergen sensitization patterns (mono- or pauci-sensitization versus polysensitization), (iii) severity of symptoms, and (iv) treatment response. In conclusion, rhinitis alone (local disease) and rhinitis with asthma multimorbidity (systemic disease) should be considered as two distinct diseases, possibly modulated by the microbiome, and may be a model for understanding the epidemics of chronic and autoimmune diseases., (© 2023 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
33. European Academy of Allergy and Clinical Immunology position paper on endoscopic scoring of nasal polyposis.
- Author
-
Gevaert P, De Craemer J, Bachert C, Blauwblomme M, Chaker A, Cingi C, Hellings PW, Hopkins C, Hox V, Fokkens WJ, Klimek L, Lund V, Mösges R, Mullol J, Pfaar O, Scadding G, Tomazic PV, Van Zele T, Vlaminck S, Wagenmann M, Toppila-Salmi S, and Alobid I
- Subjects
- Humans, Endoscopy methods, Chronic Disease, Nasal Polyps drug therapy, Rhinitis therapy, Hypersensitivity diagnosis, Sinusitis therapy
- Abstract
Nasal endoscopy is not only used for the diagnosis of chronic rhinosinusitis with nasal polyps (CRSwNP), but also for monitoring the response to therapy playing an important role in both daily practice and research. In contrast to patient-reported outcomes, endoscopic nasal polyp scoring by independent blinded readers is an objective measurement, not influenced by the placebo effect. It is safer and cheaper compared with computed tomography imaging and therefore, better suited for regular assessments of the extent of the disease. Since the early 90s, a variety of endoscopic staging methods have been proposed and used in clinical research, making it hard to compare results from different studies. This paper resulted from a task force with experts in the field of CRSwNP, originated by the Ear, Nose and Throat section of the European Academy of Allergy and Clinical Immunology and aims to provide a unified endoscopic NP scoring system that can serve as a reference standard for researchers, but also as a useful tool for practitioners involved in the management of CRSwNP., (© 2023 European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)
- Published
- 2023
- Full Text
- View/download PDF
34. Chronic Rhinosinusitis Outcome Registry (CHRINOSOR): Establishment of an International Outcome Registry Driven by mHealth Technology.
- Author
-
Seys SF, Hellings PW, Alobid I, Backer V, Bequignon E, von Buchwald C, Cavaliere C, Coste A, Deneyer L, Diamant Z, Eckl-Dorna J, Fokkens WJ, Gane S, Gevaert P, Holbaek-Haase C, Holzmeister C, Hopkins C, Hox V, Huart C, Jankowski R, Jorissen M, Kjeldsen A, Knipps L, Lange B, van der Lans R, Laulajainen-Hongisto A, Larsen K, Liu DT, Lund V, Mariën G, Masieri S, Mortuaire G, Mullol J, Reitsma S, Rombaux P, Schneider S, Steinsvik A, Tomazic PV, Toppila-Salmi SK, Van Gerven L, Van Zele T, Virkkula P, Wagenmann M, and Bachert C
- Subjects
- Adult, Humans, Adrenal Cortex Hormones therapeutic use, Chronic Disease, Nasal Polyps drug therapy, Rhinitis therapy, Rhinitis drug therapy, Sinusitis therapy, Sinusitis drug therapy
- Abstract
Background: Real-world evidence (RWE) is a valuable instrument to better understand the patient journey and effectiveness of therapies. RWE on the prevalence of uncontrolled chronic rhinosinusitis (CRS) and CRS natural course of disease across Europe is scarce. In addition, there is limited RWE that enables comparison of the effectiveness of marketed therapies including topical or systemic corticosteroids, sinus surgery, or biologics., Objective: To establish an international CHRonic rhINOSinusitis Outcome Registry (CHRINOSOR) based on real-world data collection enabled by mobile health technology., Methodology: A digital platform, Galenus Health, supporting patients and physicians in the management of chronic respiratory diseases, is used to collect data on patient profile, disease history, patient outcomes, and a set of relevant clinical outcomes. Adult patients with a diagnosis of CRS are eligible for inclusion., Results: A collaborative scientific network of 17 university ear-nose-throat (ENT) clinics from 10 European countries has been established with the aim to collect real-world data in a longitudinal and standardized manner. The Galenus Health digital platform is currently being implemented in these ENT clinics taking into account legal, privacy, and data security aspects. Up to 300 patients have already been included., Conclusions: CHRINOSOR is a collaborative effort that aims at improving our understanding of CRS, its comorbidities, and the effectiveness of its treatments. Ultimately, these insights will guide us as scientific community to develop future care pathways informed by RWE., (Copyright © 2022 American Academy of Allergy, Asthma & Immunology. Published by Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
35. The EUFOREA pocket guide for chronic rhinosinusitis.
- Author
-
Hellings PW, Fokkens WJ, Orlandi R, Adriaensen GF, Alobid I, Baroody FM, Bjermer L, Senior BA, Cervin A, Cohen NA, Constantinidis J, De Corso E, Desrosiers M, Diamant Z, Douglas RG, Gane S, Gevaert P, Han JK, Harvey RJ, Hopkins C, Kern RC, Landis BN, Lee JT, Lee SE, Leunig A, Lund VJ, Bernal-Sprekelsen M, Mullol J, Philpott C, Prokopakis E, Reitsma S, Ryan D, Salmi S, Scadding G, Schlosser RJ, Steinsvik A, Tomazic PV, Van Staeyen E, Van Zele T, Vanderveken O, Viskens AS, Conti D, and Wagenmann M
- Subjects
- Humans, Quality of Life, Chronic Disease, Rhinitis diagnosis, Rhinitis therapy, Rhinitis epidemiology, Sinusitis diagnosis, Sinusitis therapy, Sinusitis epidemiology, Hypersensitivity, Nasal Polyps diagnosis, Nasal Polyps therapy
- Abstract
Chronic rhinosinusitis (CRS) is known to affect around 5 % of the total population, with major impact on the quality of life of those severely affected (1). Despite a substantial burden on individuals, society and health economies, CRS often remains underdiagnosed, under-estimated and under-treated (2). International guidelines like the European Position Paper on Rhinosinusitis and Nasal Polyps (EPOS) (3) and the International Consensus statement on Allergy and Rhinology: Rhinosinusitis 2021 (ICAR) (4) offer physicians insight into the recommended treatment options for CRS, with an overview of effective strategies and guidance of diagnosis and care throughout the disease journey of CRS.
- Published
- 2023
- Full Text
- View/download PDF
36. Digitally-enabled, patient-centred care in rhinitis and asthma multimorbidity: The ARIA-MASK-air ® approach.
- Author
-
Bousquet J, Anto JM, Sousa-Pinto B, Czarlewski W, Bedbrook A, Haahtela T, Klimek L, Pfaar O, Kuna P, Kupczyk M, Regateiro FS, Samolinski B, Valiulis A, Yorgancioglu A, Arnavielhe S, Basagaña X, Bergmann KC, Bosnic-Anticevich S, Brussino L, Canonica GW, Cardona V, Cecchi L, Chaves-Loureiro C, Costa E, Cruz AA, Gemicioglu B, Fokkens WJ, Ivancevich JC, Kraxner H, Kvedariene V, Larenas-Linnemann DE, Laune D, Louis R, Makris M, Maurer M, Melén E, Micheli Y, Morais-Almeida M, Mullol J, Niedoszytko M, Okamoto Y, Papadopoulos NG, Patella V, Pham-Thi N, Rouadi PW, Sastre J, Scichilone N, Sheikh A, Sofiev M, Taborda-Barata L, Toppila-Salmi S, Tsiligianni I, Valovirta E, Ventura MT, Vieira RJ, Zidarn M, Amaral R, Ansotegui IJ, Bédard A, Benveniste S, Bewick M, Bindslev-Jensen C, Blain H, Bonini M, Bourret R, Braido F, Carreiro-Martins P, Charpin D, Cherrez-Ojeda I, Chivato T, Chu DK, Cingi C, Del Giacco S, de Blay F, Devillier P, De Vries G, Doulaptsi M, Doyen V, Dray G, Fontaine JF, Gomez RM, Hagemann J, Heffler E, Hofmann M, Jassem E, Jutel M, Keil T, Kritikos V, Kull I, Kulus M, Lourenço O, Mathieu-Dupas E, Menditto E, Mösges R, Murray R, Nadif R, Neffen H, Nicola S, O'Hehir R, Olze H, Palamarchuk Y, Pépin JL, Pétré B, Picard R, Pitsios C, Puggioni F, Quirce S, Raciborski F, Reitsma S, Roche N, Rodriguez-Gonzalez M, Romantowski J, Sá-Sousa A, Serpa FS, Savouré M, Shamji MH, Sova M, Sperl A, Stellato C, Todo-Bom A, Tomazic PV, Vandenplas O, Van Eerd M, Vasankari T, Viart F, Waserman S, Fonseca JA, and Zuberbier T
- Abstract
MASK-air
® , a validated mHealth app (Medical Device regulation Class IIa) has enabled large observational implementation studies in over 58,000 people with allergic rhinitis and/or asthma. It can help to address unmet patient needs in rhinitis and asthma care. MASK-air® is a Good Practice of DG Santé on digitally-enabled, patient-centred care. It is also a candidate Good Practice of OECD (Organisation for Economic Co-operation and Development). MASK-air® data has enabled novel phenotype discovery and characterisation, as well as novel insights into the management of allergic rhinitis. MASK-air® data show that most rhinitis patients (i) are not adherent and do not follow guidelines, (ii) use as-needed treatment, (iii) do not take medication when they are well, (iv) increase their treatment based on symptoms and (v) do not use the recommended treatment. The data also show that control (symptoms, work productivity, educational performance) is not always improved by medications. A combined symptom-medication score (ARIA-EAACI-CSMS) has been validated for clinical practice and trials. The implications of the novel MASK-air® results should lead to change management in rhinitis and asthma., (© 2023 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)- Published
- 2023
- Full Text
- View/download PDF
37. Real-world data using mHealth apps in rhinitis, rhinosinusitis and their multimorbidities.
- Author
-
Sousa-Pinto B, Anto A, Berger M, Dramburg S, Pfaar O, Klimek L, Jutel M, Czarlewski W, Bedbrook A, Valiulis A, Agache I, Amaral R, Ansotegui IJ, Bastl K, Berger U, Bergmann KC, Bosnic-Anticevich S, Braido F, Brussino L, Cardona V, Casale T, Canonica GW, Cecchi L, Charpin D, Chivato T, Chu DK, Cingi C, Costa EM, Cruz AA, Devillier P, Durham SR, Ebisawa M, Fiocchi A, Fokkens WJ, Gemicioğlu B, Gotua M, Guzmán MA, Haahtela T, Ivancevich JC, Kuna P, Kaidashev I, Khaitov M, Kvedariene V, Larenas-Linnemann DE, Lipworth B, Laune D, Matricardi PM, Morais-Almeida M, Mullol J, Naclerio R, Neffen H, Nekam K, Niedoszytko M, Okamoto Y, Papadopoulos NG, Park HS, Passalacqua G, Patella V, Pelosi S, Pham-Thi N, Popov TA, Regateiro FS, Reitsma S, Rodriguez-Gonzales M, Rosario N, Rouadi PW, Samolinski B, Sá-Sousa A, Sastre J, Sheikh A, Ulrik CS, Taborda-Barata L, Todo-Bom A, Tomazic PV, Toppila-Salmi S, Tripodi S, Tsiligianni I, Valovirta E, Ventura MT, Valero AA, Vieira RJ, Wallace D, Waserman S, Williams S, Yorgancioglu A, Zhang L, Zidarn M, Zuberbier J, Olze H, Antó JM, Zuberbier T, Fonseca JA, and Bousquet J
- Abstract
Digital health is an umbrella term which encompasses eHealth and benefits from areas such as advanced computer sciences. eHealth includes mHealth apps, which offer the potential to redesign aspects of healthcare delivery. The capacity of apps to collect large amounts of longitudinal, real-time, real-world data enables the progression of biomedical knowledge. Apps for rhinitis and rhinosinusitis were searched for in the Google Play and Apple App stores, via an automatic market research tool recently developed using JavaScript. Over 1500 apps for allergic rhinitis and rhinosinusitis were identified, some dealing with multimorbidity. However, only six apps for rhinitis (AirRater, AllergyMonitor, AllerSearch, Husteblume, MASK-air and Pollen App) and one for rhinosinusitis (Galenus Health) have so far published results in the scientific literature. These apps were reviewed for their validation, discovery of novel allergy phenotypes, optimisation of identifying the pollen season, novel approaches in diagnosis and management (pharmacotherapy and allergen immunotherapy) as well as adherence to treatment. Published evidence demonstrates the potential of mobile health apps to advance in the characterisation, diagnosis and management of rhinitis and rhinosinusitis patients., (© 2022 The Authors. Clinical and Translational Allergy published by John Wiley and Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)
- Published
- 2022
- Full Text
- View/download PDF
38. Behavioural patterns in allergic rhinitis medication in Europe: A study using MASK-air ® real-world data.
- Author
-
Sousa-Pinto B, Sá-Sousa A, Vieira RJ, Amaral R, Klimek L, Czarlewski W, Antó JM, Pfaar O, Bedbrook A, Kvedariene V, Ventura MT, Ansotegui IJ, Bergmann KC, Brussino L, Canonica GW, Cardona V, Carreiro-Martins P, Casale T, Cecchi L, Chivato T, Chu DK, Cingi C, Costa EM, Cruz AA, De Feo G, Devillier P, Fokkens WJ, Gaga M, Gemicioğlu B, Haahtela T, Ivancevich JC, Ispayeva Z, Jutel M, Kuna P, Kaidashev I, Kraxner H, Larenas-Linnemann DE, Laune D, Lipworth B, Louis R, Makris M, Monti R, Morais-Almeida M, Mösges R, Mullol J, Odemyr M, Okamoto Y, Papadopoulos NG, Patella V, Pham-Thi N, Regateiro FS, Reitsma S, Rouadi PW, Samolinski B, Sova M, Todo-Bom A, Taborda-Barata L, Tomazic PV, Toppila-Salmi S, Sastre J, Tsiligianni I, Valiulis A, Vandenplas O, Wallace D, Waserman S, Yorgancioglu A, Zidarn M, Zuberbier T, Fonseca JA, and Bousquet J
- Subjects
- Europe epidemiology, Habits, Histamine Antagonists therapeutic use, Humans, Rhinitis drug therapy, Rhinitis, Allergic drug therapy, Rhinitis, Allergic epidemiology
- Abstract
Background: Co-medication is common among patients with allergic rhinitis (AR), but its dimension and patterns are unknown. This is particularly relevant since AR is understood differently across European countries, as reflected by rhinitis-related search patterns in Google Trends. This study aims to assess AR co-medication and its regional patterns in Europe, using real-world data., Methods: We analysed 2015-2020 MASK-air
® European data. We compared days under no medication, monotherapy and co-medication using the visual analogue scale (VAS) levels for overall allergic symptoms ('VAS Global Symptoms') and impact of AR on work. We assessed the monthly use of different medication schemes, performing separate analyses by region (defined geographically or by Google Trends patterns). We estimated the average number of different drugs reported per patient within 1 year., Results: We analysed 222,024 days (13,122 users), including 63,887 days (28.8%) under monotherapy and 38,315 (17.3%) under co-medication. The median 'VAS Global Symptoms' was 7 for no medication days, 14 for monotherapy and 21 for co-medication (p < .001). Medication use peaked during the spring, with similar patterns across different European regions (defined geographically or by Google Trends). Oral H1 -antihistamines were the most common medication in single and co-medication. Each patient reported using an annual average of 2.7 drugs, with 80% reporting two or more., Conclusions: Allergic rhinitis medication patterns are similar across European regions. One third of treatment days involved co-medication. These findings suggest that patients treat themselves according to their symptoms (irrespective of how they understand AR) and that co-medication use is driven by symptom severity., (© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)- Published
- 2022
- Full Text
- View/download PDF
39. Distinct Chemokine Receptor Expression Profiles in De Novo DLBCL, Transformed Follicular Lymphoma, Richter's Trans-Formed DLBCL and Germinal Center B-Cells.
- Author
-
Uhl B, Prochazka KT, Pansy K, Wenzl K, Strobl J, Baumgartner C, Szmyra MM, Waha JE, Wolf A, Tomazic PV, Steinbauer E, Steinwender M, Friedl S, Weniger M, Küppers R, Pichler M, Greinix HT, Stary G, Ramsay AG, Apollonio B, Feichtinger J, Beham-Schmid C, Neumeister P, and Deutsch AJ
- Subjects
- B-Lymphocytes metabolism, Germinal Center metabolism, Humans, Neoplasm Recurrence, Local, Tumor Microenvironment, Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Follicular genetics, Lymphoma, Follicular pathology, Lymphoma, Large B-Cell, Diffuse pathology
- Abstract
Chemokine receptors and their ligands have been identified as playing an important role in the development of diffuse large B-cell lymphoma (DLBCL), follicular lymphoma, and Richter syndrome (RS). Our aim was to investigate the different expression profiles in de novo DLBCL, transformed follicular lymphoma (tFL), and RS. Here, we profiled the mRNA expression levels of 18 chemokine receptors ( CCR1 - CCR9 , CXCR1 - CXCR7 , CX3CR1 and XCR1 ) using RQ-PCR, as well as immunohistochemistry of seven chemokine receptors (CCR1, CCR4-CCR8 and CXCR2) in RS, de novo DLBCL, and tFL biopsy-derived tissues. Tonsil-derived germinal center B-cells (GC-B) served as non-neoplastic controls. The chemokine receptor expression profiles of de novo DLBCL and tFL substantially differed from those of GC-B, with at least 5-fold higher expression of 15 out of the 18 investigated chemokine receptors ( CCR1 - CCR9 , CXCR1 , CXCR2 , CXCR6 , CXCR7 , CX3CR1 and XCR1 ) in these lymphoma subtypes. Interestingly, the de novo DLBCL and tFL exhibited at least 22-fold higher expression of CCR1 , CCR5 , CCR8 , and CXCR6 compared with RS, whereas no significant difference in chemokine receptor expression profile was detected when comparing de novo DLBCL with tFL. Furthermore, in de novo DLBCL and tFLs, a high expression of CCR7 was associated with a poor overall survival in our study cohort, as well as in an independent patient cohort. Our data indicate that the chemokine receptor expression profile of RS differs substantially from that of de novo DLBCL and tFL. Thus, these multiple dysregulated chemokine receptors could represent novel clinical markers as diagnostic and prognostic tools. Moreover, this study highlights the relevance of chemokine signaling crosstalk in the tumor microenvironment of aggressive lymphomas.
- Published
- 2022
- Full Text
- View/download PDF
40. Development and validation of combined symptom-medication scores for allergic rhinitis.
- Author
-
Sousa-Pinto B, Azevedo LF, Jutel M, Agache I, Canonica GW, Czarlewski W, Papadopoulos NG, Bergmann KC, Devillier P, Laune D, Klimek L, Anto A, Anto JM, Eklund P, Almeida R, Bedbrook A, Bosnic-Anticevich S, Brough HA, Brussino L, Cardona V, Casale T, Cecchi L, Charpin D, Chivato T, Costa EM, Cruz AA, Dramburg S, Durham SR, De Feo G, Gerth van Wijk R, Fokkens WJ, Gemicioglu B, Haahtela T, Illario M, Ivancevich JC, Kvedariene V, Kuna P, Larenas-Linnemann DE, Makris M, Mathieu-Dupas E, Melén E, Morais-Almeida M, Mösges R, Mullol J, Nadeau KC, Pham-Thi N, O'Hehir R, Regateiro FS, Reitsma S, Samolinski B, Sheikh A, Stellato C, Todo-Bom A, Tomazic PV, Toppila-Salmi S, Valero A, Valiulis A, Ventura MT, Wallace D, Waserman S, Yorgancioglu A, De Vries G, van Eerd M, Zieglmayer P, Zuberbier T, Pfaar O, Almeida Fonseca J, and Bousquet J
- Subjects
- Humans, Quality of Life, Reproducibility of Results, Asthma drug therapy, Rhinitis, Rhinitis, Allergic diagnosis, Rhinitis, Allergic drug therapy
- Abstract
Background: Validated combined symptom-medication scores (CSMSs) are needed to investigate the effects of allergic rhinitis treatments. This study aimed to use real-life data from the MASK-air
® app to generate and validate hypothesis- and data-driven CSMSs., Methods: We used MASK-air® data to assess the concurrent validity, test-retest reliability and responsiveness of one hypothesis-driven CSMS (modified CSMS: mCSMS), one mixed hypothesis- and data-driven score (mixed score), and several data-driven CSMSs. The latter were generated with MASK-air® data following cluster analysis and regression models or factor analysis. These CSMSs were compared with scales measuring (i) the impact of rhinitis on work productivity (visual analogue scale [VAS] of work of MASK-air® , and Work Productivity and Activity Impairment: Allergy Specific [WPAI-AS]), (ii) quality-of-life (EQ-5D VAS) and (iii) control of allergic diseases (Control of Allergic Rhinitis and Asthma Test [CARAT])., Results: We assessed 317,176 days of MASK-air® use from 17,780 users aged 16-90 years, in 25 countries. The mCSMS and the factor analyses-based CSMSs displayed poorer validity and responsiveness compared to the remaining CSMSs. The latter displayed moderate-to-strong correlations with the tested comparators, high test-retest reliability and moderate-to-large responsiveness. Among data-driven CSMSs, a better performance was observed for cluster analyses-based CSMSs. High accuracy (capacity of discriminating different levels of rhinitis control) was observed for the latter (AUC-ROC = 0.904) and for the mixed CSMS (AUC-ROC = 0.820)., Conclusion: The mixed CSMS and the cluster-based CSMSs presented medium-high validity, reliability and accuracy, rendering them as candidates for primary endpoints in future rhinitis trials., (© 2022 The Authors. Allergy published by European Academy of Allergy and Clinical Immunology and John Wiley & Sons Ltd.)- Published
- 2022
- Full Text
- View/download PDF
41. Epithelial immune regulation of inflammatory airway diseases: Chronic rhinosinusitis with nasal polyps (CRSwNP).
- Author
-
Klimek L, Hagemann J, Welkoborsky HJ, Cuevas M, Casper I, Förster-Ruhrmann U, Klimek F, Hintschich CA, Huppertz T, Bergmann C, Tomazic PV, and Becker S
- Abstract
Background: The epithelial immune regulation is an essential and protective feature of the barrier function of the mucous membranes of the airways. Damage to the epithelial barrier can result in chronic inflammatory diseases, such as chronic rhinosinusitis (CRS) or bronchial asthma. Thymic stromal lymphopoietin (TSLP) is a central regulator in the epithelial barrier function and is associated with type 2 (T2) and non-T2 inflammation., Materials and Methods: The immunology of chronic rhinosinusitis with polyposis nasi (CRSwNP) was analyzed in a literature search, and the existing evidence was determined through searches in Medline, Pubmed as well as the national and international study and guideline registers and the Cochrane Library. Human studies or studies on human cells that were published between 2010 and 2020 and in which the immune mechanisms of TSLP in T2 and non-T2 inflammation were examined were considered., Results: TSLP is an epithelial cytokine (alarmin) and a central regulator of the immune reaction, especially in the case of chronic airway inflammation. Induction of TSLP is implicated in the pathogenesis of many diseases like CRS and triggers a cascade of subsequent inflammatory reactions., Conclusion: Treatment with TSLP-blocking monoclonal antibodies could therefore open up interesting therapeutic options. The long-term safety and effectiveness of TSLP blockade has yet to be investigated., (© Dustri-Verlag Dr. K. Feistle.)
- Published
- 2022
- Full Text
- View/download PDF
42. Septoplasties are unlikely to cause postoperative numbness of the anterior palate.
- Author
-
Andrianakis A, Bachlechner M, Kainz J, Herber V, Payer M, and Tomazic PV
- Subjects
- Humans, Hypesthesia diagnosis, Hypesthesia etiology, Hypesthesia surgery, Palate surgery, Postoperative Complications diagnosis, Postoperative Complications etiology, Retrospective Studies, Nasal Septum surgery, Rhinoplasty adverse effects, Rhinoplasty methods
- Abstract
Background: Septoplasties and septorhinoplasties are very commonly performed surgical procedures in modern aesthetic and functional medicine. Throughout the surgery, close manipulation to the incisive nerves' course is being executed. This retrospective analysis followed up on potential sensitivity disorders of the anterior palate due to nerve damage., Methods: This retrospective review of 2000 patients' charts, who had undergone the procedure of a septoplasty or septorhinoplasty between June 2013 and January 2019 was conducted at the Department of General Otorhinolaryngology, Medical University of Graz. Medical records of all included patients were reviewed with special attention to postoperative numbness of the anterior palate., Results: Among the 2000 included patients, a septoplasty was performed in 48% (n = 955), a septorhinoplasty in 35% (n = 703) and a septoplasty in combination with a functional endoscopic sinus surgery in 17% (n = 342). In total, 86% (n = 1721) showed no complications at all during the follow-up period. In 0.25% (n = 5) a sensitivity disorder of the anterior palate occurred. Of the five cases with a postoperative numbness of the anterior palate four occurred after a septoplasty and the fifth occurred following a septorhinoplasty., Conclusion: At this current time, this is the largest study investigating postoperative numbness of the anterior palate retracing septoplasty or septorhinoplasty. As a result, the currently used techniques for the operations do not pose a risk for the incisive nerve despite close surgical manipulation to the nerves' course. Nevertheless, patients should be informed and educated about the possibility of an occurring sensitivity disorder regarding the anterior palate during informed consent., (© 2021. Springer-Verlag GmbH, AT part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
43. Optic nerve injury in preoperative imaging is associated with visual improvement outcome in endoscopic optic nerve decompression.
- Author
-
Leitner I, Andrianakis A, Gellner V, Kiss P, Andrianakis D, and Tomazic PV
- Subjects
- Decompression, Surgical methods, Humans, Optic Nerve diagnostic imaging, Optic Nerve surgery, Retrospective Studies, Treatment Outcome, Visual Acuity, Optic Nerve Injuries complications, Optic Nerve Injuries diagnosis, Optic Nerve Injuries surgery
- Abstract
Objective: To evaluate potential clinical parameters having an impact on visual outcome after endoscopic optic nerve decompression in acute optic neuropathy patients., Methods: A retrospective chart review of patients with acute optic neuropathy, who underwent endoscopic optic nerve decompression between June 2001 and November 2018 at an academic center was performed. Patients were divided into groups according to visual improvement after surgical treatment (yes/no). Following clinical parameters were compared between groups: perioperative steroid use, evidence of optic nerve affection in preoperative neuroimaging, additional optic nerve sheath incision, surgery delay and preoperative C-reactive protein (CRP) levels. Further subgroups analyses were conducted based on etiology (trauma/tumor)., Results: Among 32 included cases, 16 patients (50%) reported visual improvement after endoscopic optic nerve decompression. There was no significant difference in visual improvement between etiology subgroups (trauma: n = 9/20 (45%) vs. tumor: n = 7/12 (58.3%), p = 0.465). Tumor subgroup patients with visual improvement had a significantly higher prevalence of optic nerve affection in preoperative neuroimaging than those without visual improvement (p = 0.018, φ = 0.683). Perioperative steroid administration was negatively associated with visual outcome (p = 0.034, φ = 0.375). Nerve sheath incision, surgery delay and preoperative CRP levels did not have a significant impact on visual outcome (p > 0.05)., Conclusion: Radiological findings can help as an indicator for surgical treatment since an affected optic nerve in preoperative neuroimaging resulted in better visual outcome after surgery. The use of steroids should be considered more carefully since it did not show any beneficial effect., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
44. Allergen immunotherapy in MASK-air users in real-life: Results of a Bayesian mixed-effects model.
- Author
-
Sousa-Pinto B, Azevedo LF, Sá-Sousa A, Vieira RJ, Amaral R, Klimek L, Czarlewski W, Anto JM, Bedbrook A, Kvedariene V, Ventura MT, Ansotegui IJ, Bergmann KC, Brussino L, Canonica GW, Cardona V, Carreiro-Martins P, Casale T, Cecchi L, Chivato T, Chu DK, Cingi C, Costa EM, Cruz AA, De Feo G, Devillier P, Fokkens WJ, Gaga M, Gemicioğlu B, Haahtela T, Ivancevich JC, Ispayeva Z, Jutel M, Kuna P, Kaidashev I, Kraxner H, Larenas-Linnemann DE, Laune D, Lipworth B, Louis R, Makris M, Monti R, Morais-Almeida M, Mösges R, Mullol J, Odemyr M, Okamoto Y, Papadopoulos NG, Patella V, Pham-Thi N, Regateiro FS, Reitsma S, Rouadi PW, Samolinski B, Sova M, Todo-Bom A, Taborda-Barata L, Tomazic PV, Toppila-Salmi S, Sastre J, Tsiligianni I, Valiulis A, Wallace D, Waserman S, Yorgancioglu A, Zidarn M, Zuberbier T, Fonseca JA, Bousquet J, and Pfaar O
- Abstract
Background: Evidence regarding the effectiveness of allergen immunotherapy (AIT) on allergic rhinitis has been provided mostly by randomised controlled trials, with little data from real-life studies., Objective: To compare the reported control of allergic rhinitis symptoms in three groups of users of the MASK-air
® app: those receiving sublingual AIT (SLIT), those receiving subcutaneous AIT (SCIT), and those receiving no AIT., Methods: We assessed the MASK-air® data of European users with self-reported grass pollen allergy, comparing the data reported by patients receiving SLIT, SCIT and no AIT. Outcome variables included the daily impact of allergy symptoms globally and on work (measured by visual analogue scales-VASs), and a combined symptom-medication score (CSMS). We applied Bayesian mixed-effects models, with clustering by patient, country and pollen season., Results: We analysed a total of 42,756 days from 1,093 grass allergy patients, including 18,479 days of users under AIT. Compared to no AIT, SCIT was associated with similar VAS levels and CSMS. Compared to no AIT, SLIT-tablet was associated with lower values of VAS global allergy symptoms (average difference = 7.5 units out of 100; 95% credible interval [95%CrI] = -12.1;-2.8), lower VAS Work (average difference = 5.0; 95%CrI = -8.5;-1.5), and a lower CSMS (average difference = 3.7; 95%CrI = -9.3;2.2). When compared to SCIT, SLIT-tablet was associated with lower VAS global allergy symptoms (average difference = 10.2; 95%CrI = -17.2;-2.8), lower VAS Work (average difference = 7.8; 95%CrI = -15.1;0.2), and a lower CSMS (average difference = 9.3; 95%CrI = -18.5;0.2)., Conclusion: In patients with grass pollen allergy, SLIT-tablet, when compared to no AIT and to SCIT, is associated with lower reported symptom severity. Future longitudinal studies following internationally-harmonised standards for performing and reporting real-world data in AIT are needed to better understand its 'real-world' effectiveness., (© 2022 The Authors. Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)- Published
- 2022
- Full Text
- View/download PDF
45. T2-Inflammation bei entzündlichen Atemwegserkrankungen: Grundlage neuer Behandlungsoptionen.
- Author
-
Klimek L, Hagemann J, Welkoborsky HJ, Cuevas M, Casper I, Förster-Rurmann U, Klimek F, Hintschich CA, Huppertz T, Bergmann KC, Tomazic PV, Bergmann C, and Becker S
- Subjects
- Humans, Asthma therapy, Inflammation therapy
- Abstract
Competing Interests: L. Klimek berichtet über Zuschüsse und/oder Honorare von Allergopharma, MEDA/Mylan, HAL Allergie, ALK Abelló, LETI Pharma, Stallergenes, Quintiles, Sanofi, ASIT biotech, Lofarma, Allergy Therapeut., AstraZeneca, GSK, Inmunotk, Cassella med, außerhalb der eingereichten Arbeit; und folgende Mitgliedschaften: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunolgie, HNO-BV, GPA, EAACI;Ch. Bergmann berichtet über Referentenhonorare von Sanofi Genzyme;S. Becker gibt folgende potenziellen Interessenkonflikte an: Wissenschaftliche Beratung: Novartis, Sanofi-Genzyme, Bencard Allergie; Vortragshonorare: Novartis, Sanofi-Genzyme, Bencard Allergie, HAL-Allergie, MSD, AstraZeneca; Studien: Otonomy, Regeneron, Sensorien, AstraZeneca, Auris medical;M. Cuevas berichtet über Honorare von AstraZeneca, GSK, Sanofi und Novartis;P. V. Tomazic, C. A. Hintschich, F. Klimek, U. Förster-Rurmann, I. Casper, H. J. Welkoborsky, J. Hagemann, K.-Ch. Bergmann, T. Huppertz hat keine Interessenkonflikte im Zusammenhang mit dieser Publikation.
- Published
- 2022
- Full Text
- View/download PDF
46. Preservation of nasal turbinates in endoscopic, anterior skull base surgery-yes, we can!
- Author
-
Wolf A, Andrianakis A, Tomazic PV, Mokry M, Clarici G, Holl E, Weiland T, Kiss P, Vasicek S, Brunner A, Lehner C, Schwarz J, and Gellner V
- Subjects
- Adult, Aged, Endoscopy, Female, Humans, Male, Middle Aged, Neurosurgical Procedures, Retrospective Studies, Skull Base diagnostic imaging, Skull Base surgery, Skull Base Neoplasms diagnostic imaging, Skull Base Neoplasms surgery, Turbinates surgery
- Abstract
Objective: To evaluate the frequency, type and indications of nasal turbinate (NT) resection during endoscopic, anterior skull base surgery and to analyze factors that may have an impact on the need of NT removal., Methods: In this retrospective cohort study, 306 subjects (150 males and 156 females, mean age 55.4 ± 15.3 years) who underwent multidisciplinary, transnasal, endoscopic tumor surgery of the anterior skull base using 4-handed techniques between 2011 and 2019 at the Department of Otorhinolaryngology, Medical University of Graz, were included., Results: In the majority of interventions (n = 281/306; 91.8%), all NT were preserved. Significant factors influencing the need of NT resections turned out to be type of endoscopic approach (p < 0.001; V = 0.304), sagittal (p = 0.003; d = 0.481) and transversal (p = 0.017; d = 0.533) tumor diameter, tumor type (p < 0.001; V = 0.355) and tumor location (p < 0.001; V = 0.324)., Conclusions: NT can be preserved in the majority of patients undergoing tumor resection in anterior, transnasal, skullbase surgery and routine resection of NT should be avoided. Variables that have an impact on the need of NT resections are types of endoscopic approaches, sagittal and transversal tumor extension and tumor type. These factors should be considered in planning of surgery and preoperative information of patients., (© 2021. The Author(s).)
- Published
- 2022
- Full Text
- View/download PDF
47. Comparison of two different intratympanic corticosteroid injection protocols as salvage treatments for idiopathic sudden sensorineural hearing loss.
- Author
-
Andrianakis A, Moser U, Kiss P, Holzmeister C, Andrianakis D, Tomazic PV, Wolf A, and Graupp M
- Subjects
- Adrenal Cortex Hormones therapeutic use, Audiometry, Pure-Tone, Case-Control Studies, Dexamethasone therapeutic use, Glucocorticoids therapeutic use, Humans, Injection, Intratympanic, Retrospective Studies, Salvage Therapy, Treatment Outcome, Hearing Loss, Sensorineural diagnosis, Hearing Loss, Sensorineural drug therapy, Hearing Loss, Sudden drug therapy
- Abstract
Purpose: We aimed to investigate the effect of interval length and total count of intratympanic steroid (ITS) injections in salvage treatment of patients with idiopathic sudden sensorineural hearing loss (ISSNHL)., Methods: This retrospective case-control study included 64 patients with ISSNHL, who were treated with ITS injections as salvage therapy at a tertiary referral centre. From September 2019 to December 2020, 32 patients received up to four injections every 2-4 days (revised-protocol group). These patients were 1:1 matched to patients, who received up to three injections at 1-week intervals between January 2014 and August 2019 (initial-protocol group). Hearing outcomes of the two groups were compared., Results: Both ITS salvage treatment protocols resulted in a statistically significant hearing improvement (p < 0.05). The initial-protocol declined hearing thresholds by 12 ± 11.7 dB (p < 0.001, d = 1, P = 99%). Mean hearing function was improved by 13.4 ± 19.1 dB in the revised-protocol group [p < 0.001, d = 0.7, P = 98%]. A clinically significant hearing improvement (> 10 dB) was seen in 18 patients (58.1%) in the initial-protocol group and in 14 patients (41.9%) in the revised-protocol group. A comparison of the hearing outcomes between protocol groups revealed no statistically significant differences (p > 0.05)., Conclusion: These results indicate that a shorter injection interval does not lead to better hearing outcomes in ITS salvage treatment for ISSNHL. Moreover, fewer ITS injections may reduce costs, physical/mental stress of the patients and lower the risk of persistent tympanic perforations., (© 2021. The Author(s), under exclusive licence to Springer-Verlag GmbH, DE part of Springer Nature.)
- Published
- 2022
- Full Text
- View/download PDF
48. Observing the brain pulsating.
- Author
-
Andrianakis A and Tomazic PV
- Subjects
- Humans, Brain diagnostic imaging
- Published
- 2021
- Full Text
- View/download PDF
49. Sinonasal mucosal melanoma: treatment strategies and survival rates for a rare disease entity : A single center experience and review of literature.
- Author
-
Andrianakis A, Kiss P, Pomberger M, Wolf A, Thurnher D, and Tomazic PV
- Subjects
- Humans, Nasal Mucosa, Prospective Studies, Rare Diseases, Retrospective Studies, Survival Rate, Melanoma therapy, Paranasal Sinus Neoplasms therapy
- Abstract
Background: Sinonasal mucosal melanoma (SNMM) is a rare disease entity comprising 0.4-1.3% of all melanomas. Surgery with free margins has been the primary treatment over decades. Neither the addition of radiotherapy nor chemotherapy could significantly improve outcome rates of this devastating malignancy. This study presents our clinical experience with SNMM over a 19-year period and summarizes the current body of literature on SNMM., Methods: This retrospective analysis included 12 patients with SNMM treated from 2001 to 2019 at an academic center. Additionally, a literature review of the last 29 years on treatment and survival data of SNMM was conducted., Results: Main initial symptoms were epistaxis and nasal obstruction. Of the patients 9 underwent endoscopic surgery, 6 received adjuvant therapy. 3 patients who did not undergo surgery, received chemoradiotherapy, radiotherapy alone, and chemotherapy alone, respectively. At the time of diagnosis 2 patients had distant metastases and 4 patients developed distant metastases during the course of the disease. Mean overall survival (OS) was 30.6 months, 3‑year and 5‑year OS were 25%, and 18.2%, respectively., Conclusion: Unspecific symptoms and hidden anatomic locations lead to delayed diagnosis and increased rates of metastatic dissemination. Distant metastasis is the main treatment failure in SNMM. Surgery with free margins remains the primary treatment for SNMM. Adjuvant radiotherapy might improve local control in individual cases but efficient systemic therapy is needed to improve outcome rates. To evaluate and define more effective targeted treatment options and improve outcome rates, homogeneous data and prospective multicentric analysis are needed., (© 2021. The Author(s).)
- Published
- 2021
- Full Text
- View/download PDF
50. Validity, reliability, and responsiveness of daily monitoring visual analog scales in MASK-air®.
- Author
-
Sousa-Pinto B, Eklund P, Pfaar O, Klimek L, Zuberbier T, Czarlewski W, Bédard A, Bindslev-Jensen C, Bedbrook A, Bosnic-Anticevich S, Brussino L, Cardona V, Cruz AA, de Vries G, Devillier P, Fokkens WJ, Fuentes-Pérez JM, Gemicioğlu B, Haahtela T, Huerta-Villalobos YR, Ivancevich JC, Kull I, Kuna P, Kvedariene V, Larenas Linnemann DE, Laune D, Makris M, Melén E, Morais-Almeida M, Mösges R, Mullol J, O'Hehir RE, Papadopoulos NG, Pereira AM, Prokopakis EP, Psarros F, Regateiro FS, Reitsma S, Samolinski B, Scichilone N, da Silva J, Stellato C, Todo-Bom A, Tomazic PV, Salmi ST, Valero A, Valiulis A, Valovirta E, van Eerd M, Ventura MT, Yorgancioglu A, Basagaña X, Antó JM, Bousquet J, and Fonseca JA
- Abstract
Background: MASK-air® is an app that supports allergic rhinitis patients in disease control. Users register daily allergy symptoms and their impact on activities using visual analog scales (VASs). We aimed to assess the concurrent validity, reliability, and responsiveness of these daily VASs., Methods: Daily monitoring VAS data were assessed in MASK-air® users with allergic rhinitis. Concurrent validity was assessed by correlating daily VAS values with those of the EuroQol-5 Dimensions (EQ-5D) VAS, the Control of Allergic Rhinitis and Asthma Test (CARAT) score, and the Work Productivity and Activity Impairment Allergic Specific (WPAI-AS) Questionnaire (work and activity impairment scores). Intra-rater reliability was assessed in users providing multiple daily VASs within the same day. Test-retest reliability was tested in clinically stable users, as defined by the EQ-5D VAS, CARAT, or "VAS Work" (i.e., VAS assessing the impact of allergy on work). Responsiveness was determined in users with two consecutive measurements of EQ-5D-VAS or "VAS Work" indicating clinical change., Results: A total of 17,780 MASK-air® users, with 317,176 VAS days, were assessed. Concurrent validity was moderate-high (Spearman correlation coefficient range: 0.437-0.716). Intra-rater reliability intraclass correlation coefficients (ICCs) ranged between 0.870 (VAS assessing global allergy symptoms) and 0.937 (VAS assessing allergy symptoms on sleep). Test-retest reliability ICCs ranged between 0.604 and 0.878-"VAS Work" and "VAS asthma" presented the highest ICCs. Moderate/large responsiveness effect sizes were observed-the sleep VAS was associated with lower responsiveness, while the global allergy symptoms VAS demonstrated higher responsiveness., Conclusion: In MASK-air®, daily monitoring VASs have high intra-rater reliability and moderate-high validity, reliability, and responsiveness, pointing to a reliable measure of symptom loads., Competing Interests: Sinthia Bosnic‐Anticevich reports grants from TEVA and personal fees from TEVA, AstraZeneca, Boehringer Ingelheim, GSK, Sanofi, Mylan. Jean Bousquet reports personal fees from Chiesi, Cipla, Hikma, Menarini, Mundipharma, Mylan, Novartis, Sanofi‐Aventis, Takeda, Teva, Uriach, other from KYomed‐Innov, and personal fees from Purina. Victoria Cardona reports personal fees from ALK, Allergy Therapeutics, LETI, Thermofisher, Merck, Astrazeneca, and GSK. Alvaro A Cruz reports grants and personal fees from GlaxoSmithKline, personal fees from Sanofi, AstraZeneca, Novartis, Chiesi, Boehringer Ingelheim, Mylan, and Eurofarma. Philippe Devillier reports personal fees from Mylan. Bilun Gemicioğlu reports grants from AstraZeneca, MSD, GSK, Deva, Novartis, and Abdi Ibrahim. Tari Haahtela reports personal fees from GSK, Mundipharma, Orion Pharma, Sanofi, Juan Carlos Ivancevich reports personal fees from Sanofi, Faes Farma, Laboratorios Casasco, Abbott, Ludger Klimek reports grants and personal fees from Allergopharma, LETI Pharma, MEDA/Mylan, and Sanofi, personal fees from Allergy Therapeut, Casssela med, and HAL Allergie, grants from ALK Abelló, Stallergenes, Quintiles, ASIT biotech, Lofarma, AstraZeneca, GSK, Inmunotk, and Membership: AeDA, DGHNO, Deutsche Akademie für Allergologie und klinische Immunologie, HNO‐BV, GPA, and EAACI. Piotr Kuna reports personal fees from Adamed, AstraZeneca, Berlin Chemie Menarini, Boehringer Ingelheim, GSK, HAL Allergy, Lekam, Mylan, Novartis, and Teva. Désirée Larenas Linnemann reports personal fees from Allakos, Amstrong, Astrazeneca, DBV Technologies, Grunenthal, GSK, Mylan, Menarini, MSD, Novartis, Pfizer, Sanofi, Siegfried, UCB, Alakos, and Gossamer, grants from Sanofi, Astrazeneca, Novartis, Circassia, UCB, GSK, TEVA, and Purina Institute. Michael Makris reports personal fees from Novartis, AstraZeneca, GSK, Chiesi, Menarini, Sanofi Genzyme, and Pfizer. Joaquin Mullol reports personal fees and other from SANOFI‐GENZYME & REGENERON, Genentech‐Roche & NOVARTIS, grants and personal fees from VIATRIS (MEDA‐MYLAN Pharma) and URIACH Group, and personal fees from Mitsubishi‐Tanabe, Menarini, UCB, AstraZeneca, and GSK. Oliver Pfaar reports grants and personal fees from ALK‐Abelló, Allergopharma, Stallergenes Greer, HAL Allergy Holding B.V./HAL Allergie GmbH, Bencard Allergie GmbH/Allergy Therapeutics, Lofarma, Anergis S.A., ASIT Biotech Tools S.A., Laboratorios LETI/LETI Pharma, and Glaxo Smith Kline, grants from Biomay, Circassia, Pohl‐Boskamp, and Inmunotek S.L., and personal fees from MEDA Pharma/MYLAN, Mobile Chamber Experts (a GA2LEN Partner), Indoor Biotechnologies, Astellas Pharma Global, EUFOREA, ROXALL Medizin, Novartis, Sanofi‐Aventis and Sanofi‐Genzyme, Med Update Europe GmbH, streamedup! GmbH, John Wiley and Sons, AS, and Paul‐Martini‐Stiftung (PMS). Nikolaos G. Papadopoulos reports personal fees from Novartis, Nutricia, HAL, MENARINI/FAES FARMA, SANOFI, MYLAN/MEDA, BIOMAY, AstraZeneca, GSK, MSD, ASIT BIOTECH, and Boehringer Ingelheim and grants from Gerolymatos International SA, and Capricare. Boleslaw Samolinski reports personal fees from Allergopharma, Polpharma, Viatris, TEVA, ADAMED, patient ombudsman, and Polish Allergology Society, grants from AstraZeneca, National Health Programme, and grants and personal fees from AstraZeneca. Ana Todo‐Bom reports grants and personal fees from AstraZeneca, GSK (GlaxoSmithKline), Novartis, Sanofi, Teva, and Mundipharma, personal fees from Bial, and grants from Leti. Torsten Zuberbier reports personal fees from Bayer Health Care, FAES, Novartis, Henkel, Novartis, from Henkel, AstraZeneca, AbbVie Fee for talk, ALK Fee for talk, Almirall Fee for talk, Astellas Fee for talk, Bayer Health Care Fee for talk, Bencard Fee for talk, Berlin Chemie Fee for talk, FAES Fee for talk, HAL Fee for talk, Leti Fee for talk, Meda Fee for talk, Menarini Fee for talk, Merck Fee for talk, MSD Fee for talk, Novartis Fee for talk, Pfizer Fee for talk, Sanofi Fee for talk, Stallergenes Fee for talk, Takeda Fee for talk, Teva Fee for talk, UCB Fee for talk, Henkel Fee for talk, Kryolan Fee for talk, and L'Oréal Fee for talk., (© 2021 The Authors. Clinical and Translational Allergy published by John Wiley and Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.)
- Published
- 2021
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.